1
|
Albertelli M, Rossi G, Nazzari E, Genova C, Biello F, Rijavec E, Dal Bello MG, Patti L, Tagliamento M, Barletta G, Morabito P, Boschetti M, Dotto A, Campana D, Ferone D, Grossi F. Improved overall survival in patients developing endocrine toxicity during treatment with nivolumab for advanced non-small cell lung cancer in a prospective study. J Endocrinol Invest 2024:10.1007/s40618-023-02268-0. [PMID: 38683497 DOI: 10.1007/s40618-023-02268-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/19/2023] [Accepted: 12/01/2023] [Indexed: 05/01/2024]
Abstract
PURPOSE Immune checkpoint inhibitors (ICPIs) disrupting PD-1/PD-L1 axis have revolutionized the management of advanced non-small cell lung cancer (NSCLC). Some studies identified the development of endocrine toxicity as predictor of better survival in cancer patients treated with ICPIs. The aim of study was to evaluate survival and new onset of immune-related endocrine adverse events (irAEs) in patients treated with nivolumab for advanced NSCLC. METHODS In a prospective study, 73 patients with previously treated advanced NSCLC received nivolumab in monotherapy. Blood samples were collected at each cycle to monitor thyroid autoimmunity, thyroid, adrenal and somatotroph axes, while thyroid morphology was evaluated by ultrasonography. RESULTS An impaired thyroid function was recorded in 23.4% of patients (n = 15). Eight patients developed asymptomatic transient thyrotoxicosis (ATT) evolving to hypothyroidism in 50% of cases. In addition, seven patients developed overt hypothyroidism without ATT and with negative autoantibodies. Patients who developed hypothyroidism proved to have better overall survival (OS) as compared with non-developers at both univariate (p = 0.021) and multivariate analyses (p = 0.023). The survival curve of patients with reduced IGF-I at baseline, or displaying its reduction during the follow-up, showed significantly reduced median survival compared to patients with normal/high IGF-I levels (p = 0.031). CONCLUSIONS Thyroid function abnormalities are the major irAEs in patients treated with nivolumab, and hypothyroidism onset is associated with prolonged survival. Our findings indicate that the development of hypothyroidism is a positive predictive biomarker of nivolumab antitumor efficacy in patients with NSCLC. Low IGF-I levels could represent a negative prognostic factor during nivolumab therapy.
Collapse
Affiliation(s)
- M Albertelli
- Endocrinology Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
- Endocrinology Unit, Department of Internal Medicine and Medical Specialties (DiMI), University of Genova, Viale Benedetto XV, 6, 16132, Genova, Italy.
| | - G Rossi
- Lung Cancer Unit, Department of Oncology, IRCCS Ospedale Policlinico San Martino, Genova, Italy
| | - E Nazzari
- Endocrinology Unit, Department of Internal Medicine and Medical Specialties (DiMI), University of Genova, Viale Benedetto XV, 6, 16132, Genova, Italy
| | - C Genova
- Academic Oncology Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy
- Department of Internal Medicine and Medical Specialties (DiMI), Università Degli Studi di Genova, Genova, Italy
| | - F Biello
- Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy
| | - E Rijavec
- Unit of Medical Oncology, Department of Medicine and Surgery, University of Insubria, ASST dei Sette Laghi, Varese, Italy
| | - M G Dal Bello
- Lung Cancer Unit, Department of Oncology, IRCCS Ospedale Policlinico San Martino, Genova, Italy
| | - L Patti
- Endocrinology Unit, Department of Internal Medicine and Medical Specialties (DiMI), University of Genova, Viale Benedetto XV, 6, 16132, Genova, Italy
| | - M Tagliamento
- Academic Oncology Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy
- Department of Internal Medicine and Medical Specialties (DiMI), Università Degli Studi di Genova, Genova, Italy
| | - G Barletta
- Lung Cancer Unit, Department of Oncology, IRCCS Ospedale Policlinico San Martino, Genova, Italy
| | - P Morabito
- Lung Cancer Unit, Department of Oncology, IRCCS Ospedale Policlinico San Martino, Genova, Italy
| | - M Boschetti
- Endocrinology Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy
- Endocrinology Unit, Department of Internal Medicine and Medical Specialties (DiMI), University of Genova, Viale Benedetto XV, 6, 16132, Genova, Italy
| | - A Dotto
- Endocrinology Unit, Department of Internal Medicine and Medical Specialties (DiMI), University of Genova, Viale Benedetto XV, 6, 16132, Genova, Italy
| | - D Campana
- UO Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
| | - D Ferone
- Endocrinology Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy
- Endocrinology Unit, Department of Internal Medicine and Medical Specialties (DiMI), University of Genova, Viale Benedetto XV, 6, 16132, Genova, Italy
| | - F Grossi
- Unit of Medical Oncology, Department of Medicine and Surgery, University of Insubria, ASST dei Sette Laghi, Varese, Italy
| |
Collapse
|
2
|
Andrini E, Lamberti G, Argalia G, Fortunati E, Ambrosini V, Fanti S, Campana D, Ardizzoni A. MA01.08 Impact of [18F]FDG PET/CT-derived Metabolic Parameters on Outcomes in Extensive-stage SCLC. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
3
|
Andrini E, Lamberti G, Argalia G, Fortunati E, Ambrosini V, Fanti S, Ardizzoni A, Campana D. 149P Total metabolic tumor volume: A new potential prognostic factor in SCLC. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.02.180] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
4
|
Adams JH, Ahmad S, Allard D, Anzalone A, Bacholle S, Barrillon P, Bayer J, Bertaina M, Bisconti F, Blaksley C, Blin-Bondil S, Bobík P, Cafagna F, Campana D, Capel F, Casolino M, Cassardo C, Catalano C, Cremonini R, Dagoret-Campagne S, Danto P, del Peral L, de la Taille C, Díaz Damian A, Dupieux M, Ebersoldt A, Ebisuzaki T, Eser J, Evrard J, Fenu F, Ferrarese S, Fornaro C, Fouka M, Gorodetzky P, Guarino F, Guzman A, Hachisu Y, Haungs A, Judd E, Jung A, Karczmarczyk J, Kawasaki Y, Klimov PA, Kuznetsov E, Mackovjak S, Manfrin M, Marcelli L, Medina-Tanco G, Mercier K, Merino A, Mernik T, Miyamoto H, Morales de los Ríos JA, Moretto C, Mot B, Neronov A, Ohmori H, Olinto AV, Osteria G, Panico B, Parizot E, Paul T, Picozza P, Piotrowski LW, Plebaniak Z, Pliego S, Prat P, Prévôt G, Prieto H, Putis M, Rabanal J, Ricci M, Rojas J, Rodríguez Frías MD, Roudil G, Sáez Cano G, Sahnoun Z, Sakaki N, Sanchez JC, Santangelo A, Sarazin F, Scotti V, Shinozaki K, Silva H, Soriano JF, Suino G, Szabelski J, Toscano S, Tabone I, Takizawa Y, von Ballmoos P, Wiencke L, Wille M, Zotov M. A Review of the EUSO-Balloon Pathfinder for the JEM-EUSO Program. Space Sci Rev 2022; 218:3. [PMID: 35153338 PMCID: PMC8807436 DOI: 10.1007/s11214-022-00870-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 03/24/2021] [Accepted: 12/31/2021] [Indexed: 06/14/2023]
Abstract
EUSO-Balloon is a pathfinder for JEM-EUSO, the mission concept of a spaceborne observatory which is designed to observe Ultra-High Energy Cosmic Ray (UHECR)-induced Extensive Air Showers (EAS) by detecting their UltraViolet (UV) light tracks "from above." On August 25, 2014, EUSO-Balloon was launched from Timmins Stratospheric Balloon Base (Ontario, Canada) by the balloon division of the French Space Agency CNES. After reaching a floating altitude of 38 km, EUSO-Balloon imaged the UV light in the wavelength range ∼290-500 nm for more than 5 hours using the key technologies of JEM-EUSO. The flight allowed a good understanding of the performance of the detector to be developed, giving insights into possible improvements to be applied to future missions. A detailed measurement of the photoelectron counts in different atmospheric and ground conditions was achieved. By means of the simulation of the instrument response and by assuming atmospheric models, the absolute intensity of diffuse light was estimated. The instrument detected hundreds of laser tracks with similar characteristics to EASs shot by a helicopter flying underneath. These are the first recorded laser tracks measured from a fluorescence detector looking down on the atmosphere. The reconstruction of the direction of the laser tracks was performed. In this work, a review of the main results obtained by EUSO-Balloon is presented as well as implications for future space-based observations of UHECRs.
Collapse
Affiliation(s)
- J. H. Adams
- University of Alabama in Huntsville, Huntsville, USA
| | - S. Ahmad
- Omega, Ecole Polytechnique, CNRS/IN2P3, Palaiseau, France
| | - D. Allard
- APC, Univ. Paris Diderot, CNRS/IN2P3, CEA/Irfu, Obs de Paris, Paris, France
| | - A. Anzalone
- INAF - Istituto di Astrofisica Spaziale e Fisica Cosmica di Palermo, Palermo, Italy
- Istituto Nazionale di Fisica Nucleare - Sezione di Catania, Catania, Italy
| | - S. Bacholle
- APC, Univ. Paris Diderot, CNRS/IN2P3, CEA/Irfu, Obs de Paris, Paris, France
| | - P. Barrillon
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, Orsay, France
| | - J. Bayer
- Institute for Astronomy and Astrophysics, University of Tübingen, Tübingen, Germany
| | - M. Bertaina
- Istituto Nazionale di Fisica Nucleare - Sezione di Torino, Torino, Italy
- Dipartimento di Fisica, Universitá di Torino, Torino, Italy
| | - F. Bisconti
- Dipartimento di Fisica, Universitá di Torino, Torino, Italy
- Karlsruhe Institute of Technology, Karlsruhe, Germany
| | - C. Blaksley
- APC, Univ. Paris Diderot, CNRS/IN2P3, CEA/Irfu, Obs de Paris, Paris, France
| | - S. Blin-Bondil
- Omega, Ecole Polytechnique, CNRS/IN2P3, Palaiseau, France
| | - P. Bobík
- Institute of Experimental Physics, Slovak Academy of Sciences, Košice, Slovakia
| | - F. Cafagna
- Istituto Nazionale di Fisica Nucleare - Sezione di Bari, Bari, Italy
| | - D. Campana
- Istituto Nazionale di Fisica Nucleare - Sezione di Napoli, Naples, Italy
| | - F. Capel
- KTH Royal Institute of Technology, Stockholm, Sweden
| | - M. Casolino
- RIKEN, 2-1 Hirosawa, Wako, Saitama Japan
- Istituto Nazionale di Fisica Nucleare - Sezione di Roma Tor Vergata, Roma, Italy
| | - C. Cassardo
- Dipartimento di Fisica, Universitá di Torino, Torino, Italy
| | - C. Catalano
- IRAP, Université de Toulouse, CNRS, Toulouse, France
| | - R. Cremonini
- Dipartimento di Fisica, Universitá di Torino, Torino, Italy
| | | | - P. Danto
- CNES, 18 avenue Edouard Belin, Toulouse, France
| | | | | | | | - M. Dupieux
- IRAP, Université de Toulouse, CNRS, Toulouse, France
| | - A. Ebersoldt
- Karlsruhe Institute of Technology, Karlsruhe, Germany
| | | | - J. Eser
- Colorado School of Mines, Golden, USA
| | - J. Evrard
- CNES, 18 avenue Edouard Belin, Toulouse, France
| | - F. Fenu
- Istituto Nazionale di Fisica Nucleare - Sezione di Torino, Torino, Italy
- Dipartimento di Fisica, Universitá di Torino, Torino, Italy
| | - S. Ferrarese
- Dipartimento di Fisica, Universitá di Torino, Torino, Italy
| | | | - M. Fouka
- Center of Research in Astronomy, Astrophysics, and Geophysics, Algiers, Algeria
| | - P. Gorodetzky
- APC, Univ. Paris Diderot, CNRS/IN2P3, CEA/Irfu, Obs de Paris, Paris, France
| | - F. Guarino
- Istituto Nazionale di Fisica Nucleare - Sezione di Napoli, Naples, Italy
- Dipartimento di Scienze Fisiche, Universitá di Napoli Federico II, Naples, Italy
| | - A. Guzman
- Institute for Astronomy and Astrophysics, University of Tübingen, Tübingen, Germany
| | - Y. Hachisu
- RIKEN, 2-1 Hirosawa, Wako, Saitama Japan
| | - A. Haungs
- Karlsruhe Institute of Technology, Karlsruhe, Germany
| | - E. Judd
- Space Sciences Laboratory, University of California, Berkeley, CA USA
| | - A. Jung
- APC, Univ. Paris Diderot, CNRS/IN2P3, CEA/Irfu, Obs de Paris, Paris, France
| | | | | | - P. A. Klimov
- Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, Moscow, Russia
| | - E. Kuznetsov
- University of Alabama in Huntsville, Huntsville, USA
| | - S. Mackovjak
- Institute of Experimental Physics, Slovak Academy of Sciences, Košice, Slovakia
| | - M. Manfrin
- Dipartimento di Fisica, Universitá di Torino, Torino, Italy
| | - L. Marcelli
- Istituto Nazionale di Fisica Nucleare - Sezione di Roma Tor Vergata, Roma, Italy
| | - G. Medina-Tanco
- Universidad Nacional Autónoma de México, Mexico City, Mexico
| | - K. Mercier
- CNES, 18 avenue Edouard Belin, Toulouse, France
| | | | - T. Mernik
- Institute for Astronomy and Astrophysics, University of Tübingen, Tübingen, Germany
| | - H. Miyamoto
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, Orsay, France
- Dipartimento di Fisica, Universitá di Torino, Torino, Italy
| | | | - C. Moretto
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, Orsay, France
| | - B. Mot
- IRAP, Université de Toulouse, CNRS, Toulouse, France
| | - A. Neronov
- ISDC Data Centre for Astrophysics, Versoix, Switzerland
| | - H. Ohmori
- RIKEN, 2-1 Hirosawa, Wako, Saitama Japan
| | | | - G. Osteria
- Istituto Nazionale di Fisica Nucleare - Sezione di Napoli, Naples, Italy
| | - B. Panico
- Istituto Nazionale di Fisica Nucleare - Sezione di Napoli, Naples, Italy
- Dipartimento di Scienze Fisiche, Universitá di Napoli Federico II, Naples, Italy
| | - E. Parizot
- APC, Univ. Paris Diderot, CNRS/IN2P3, CEA/Irfu, Obs de Paris, Paris, France
| | - T. Paul
- Lehman College, City University of New York, New York, USA
| | - P. Picozza
- RIKEN, 2-1 Hirosawa, Wako, Saitama Japan
- Istituto Nazionale di Fisica Nucleare - Sezione di Roma Tor Vergata, Roma, Italy
- Dipartimento di Fisica, Universitá di Roma Tor Vergata, Roma, Italy
| | | | - Z. Plebaniak
- Dipartimento di Fisica, Universitá di Torino, Torino, Italy
- National Centre for Nuclear Research, Lodz, Poland
| | - S. Pliego
- Universidad Nacional Autónoma de México, Mexico City, Mexico
| | - P. Prat
- APC, Univ. Paris Diderot, CNRS/IN2P3, CEA/Irfu, Obs de Paris, Paris, France
| | - G. Prévôt
- APC, Univ. Paris Diderot, CNRS/IN2P3, CEA/Irfu, Obs de Paris, Paris, France
| | - H. Prieto
- Universidad de Alcalá, Madrid, Spain
| | - M. Putis
- Institute of Experimental Physics, Slovak Academy of Sciences, Košice, Slovakia
| | - J. Rabanal
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, Orsay, France
| | - M. Ricci
- Istituto Nazionale di Fisica Nucleare, Laboratori Nazionali di Frascati, Frascati, Italy
| | - J. Rojas
- Universidad Nacional Autónoma de México, Mexico City, Mexico
| | | | - G. Roudil
- IRAP, Université de Toulouse, CNRS, Toulouse, France
| | | | - Z. Sahnoun
- Center of Research in Astronomy, Astrophysics, and Geophysics, Algiers, Algeria
| | - N. Sakaki
- RIKEN, 2-1 Hirosawa, Wako, Saitama Japan
| | - J. C. Sanchez
- Universidad Nacional Autónoma de México, Mexico City, Mexico
| | - A. Santangelo
- Institute for Astronomy and Astrophysics, University of Tübingen, Tübingen, Germany
| | | | - V. Scotti
- Istituto Nazionale di Fisica Nucleare - Sezione di Napoli, Naples, Italy
- Dipartimento di Scienze Fisiche, Universitá di Napoli Federico II, Naples, Italy
| | - K. Shinozaki
- Dipartimento di Fisica, Universitá di Torino, Torino, Italy
- National Centre for Nuclear Research, Lodz, Poland
| | - H. Silva
- Universidad Nacional Autónoma de México, Mexico City, Mexico
| | | | - G. Suino
- Dipartimento di Fisica, Universitá di Torino, Torino, Italy
| | - J. Szabelski
- National Centre for Nuclear Research, Lodz, Poland
| | - S. Toscano
- ISDC Data Centre for Astrophysics, Versoix, Switzerland
| | - I. Tabone
- Dipartimento di Fisica, Universitá di Torino, Torino, Italy
| | | | | | | | - M. Wille
- ECAP, University of Erlangen-Nuremberg, Erlangen, Germany
| | - M. Zotov
- Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, Moscow, Russia
| |
Collapse
|
5
|
Rossi RE, Milanetto AC, Andreasi V, Campana D, Coppa J, Nappo G, Rinzivillo M, Invernizzi P, Modica R, David A, Partelli S, Lamberti G, Mazzaferro V, Zerbi A, Panzuto F, Pasquali C, Falconi M, Massironi S. Risk of preoperative understaging of duodenal neuroendocrine neoplasms: a plea for caution in the treatment strategy. J Endocrinol Invest 2021; 44:2227-2234. [PMID: 33651317 DOI: 10.1007/s40618-021-01528-1] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/17/2020] [Accepted: 02/04/2021] [Indexed: 02/05/2023]
Abstract
PURPOSE Pretreatment staging is the milestone for planning either surgical or endoscopic treatment in duodenal neuroendocrine neoplasms (dNENs). Herein, a series of surgically treated dNEN patients was evaluated to assess the concordance between the pre- and postsurgical staging. METHODS Retrospective analysis of patients with a histologically confirmed diagnosis of dNENs, who underwent surgical resection observed at eight Italian tertiary referral centers. The presurgical TNM stage, based on the radiological and functional imaging, was compared with the pathological TNM stage, after surgery. RESULTS From 2000 to 2019, 109 patients were included. Sixty-six patients had G1, 26 a G2, 7 a G3 dNEN (Ki-67 not available in 10 patients). In 46/109 patients (42%) there was disagreement between the pre- and postsurgical staging, being it understaged in 42 patients (38%), overstaged in 4 (3%). As regards understaging, in 25 patients (22.9%), metastatic loco-regional nodes (N) resulted undetected at both radiological and functional imaging. Understaging due to the presence of distal micrometastases (M) was observed in 2 cases (1.8%). Underestimation of tumor extent (T) was observed in 12 patients (11%); in three cases the tumor was understaged both in T and N extent. CONCLUSIONS Conventional imaging has a poor detection rate for loco-regional nodes and micrometastases in the presurgical setting of the dNENs. These results represent important advice when local conservative approaches, such as endoscopy or local surgical excision are considered and it represents a strong recommendation to include endoscopic ultrasound in the preoperative tools for a more accurate local staging.
Collapse
Affiliation(s)
- R E Rossi
- Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
- HBP Surgery, Hepatology and Liver Transplantation Unit, ENETS Center of Excellence, Fondazione IRCCS Istituto Nazionale Tumori (INT, National Cancer Institute), Milan, Italy.
| | - A C Milanetto
- Pancreatic and Endocrine Digestive Surgical Unit, Department of Surgery, Oncology and Gastroenterology, Università degli Studi di Padova, Padua, Italy
| | - V Andreasi
- Pancreatic Surgery Unit, Pancreas Translational and Clinical Research Center, ENETS Center of Excellence, San Raffaele Scientific Institute, "Vita-Salute" University, Milan, Italy
| | - D Campana
- Department of Experimental, Diagnostic and Specialty Medicine, ENETS Center of Excellence, Bologna University, St. Orsola-Malpighi University Hospital, Bologna, Italy
| | - J Coppa
- HBP Surgery, Hepatology and Liver Transplantation Unit, ENETS Center of Excellence, Fondazione IRCCS Istituto Nazionale Tumori (INT, National Cancer Institute), Milan, Italy
| | - G Nappo
- Pancreatic Surgery, Humanitas Clinical, and Research Center-IRCCS, ENETS Center of Excellence, Humanitas University, Milan, Rozzano, Italy
| | - M Rinzivillo
- Digestive Disease Unit, ENETS Center of Excellence, Sant'Andrea University Hospital, Rome, Italy
| | - P Invernizzi
- Division of Gastroenterology, San Gerardo Hospital, Bicocca School of Medicine, University of Milano, Monza, Italy
| | - R Modica
- Division of Endocrinology, Department of Clinical Medicine and Surgery, ENETS Center of Excellence, University "Federico II" of Naples, Naples, Italy
| | - A David
- Pancreatic and Endocrine Digestive Surgical Unit, Department of Surgery, Oncology and Gastroenterology, Università degli Studi di Padova, Padua, Italy
| | - S Partelli
- Pancreatic Surgery Unit, Pancreas Translational and Clinical Research Center, ENETS Center of Excellence, San Raffaele Scientific Institute, "Vita-Salute" University, Milan, Italy
| | - G Lamberti
- Department of Experimental, Diagnostic and Specialty Medicine, ENETS Center of Excellence, Bologna University, St. Orsola-Malpighi University Hospital, Bologna, Italy
| | - V Mazzaferro
- HBP Surgery, Hepatology and Liver Transplantation Unit, ENETS Center of Excellence, Fondazione IRCCS Istituto Nazionale Tumori (INT, National Cancer Institute), Milan, Italy
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
| | - A Zerbi
- Pancreatic Surgery, Humanitas Clinical, and Research Center-IRCCS, ENETS Center of Excellence, Humanitas University, Milan, Rozzano, Italy
| | - F Panzuto
- Digestive Disease Unit, ENETS Center of Excellence, Sant'Andrea University Hospital, Rome, Italy
| | - C Pasquali
- Pancreatic and Endocrine Digestive Surgical Unit, Department of Surgery, Oncology and Gastroenterology, Università degli Studi di Padova, Padua, Italy
| | - M Falconi
- Pancreatic Surgery Unit, Pancreas Translational and Clinical Research Center, ENETS Center of Excellence, San Raffaele Scientific Institute, "Vita-Salute" University, Milan, Italy
| | - S Massironi
- Division of Gastroenterology, San Gerardo Hospital, Bicocca School of Medicine, University of Milano, Monza, Italy
| |
Collapse
|
6
|
Panzuto F, Maccauro M, Campana D, Faggiano A, Massironi S, Pusceddu S, Spada F, Ferone D, Modica R, Grana CM, Ferolla P, Rinzivillo M, Badalamenti G, Zatelli MC, Gelsomino F, De Carlo E, Bartolomei M, Brizzi MP, Cingarlini S, Versari A, Fanciulli G, Arvat E, Merola E, Cives M, Tafuto S, Baldari S, Falconi M. Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet). J Endocrinol Invest 2021; 44:989-994. [PMID: 32803662 PMCID: PMC7429140 DOI: 10.1007/s40618-020-01393-4] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/17/2020] [Accepted: 08/09/2020] [Indexed: 02/08/2023]
Abstract
INTRODUCTION The organization of the healthcare system has significantly changed after the recent COVID-19 outbreak, with a negative impact on the management of oncological patients. The present survey reports data collected by the Italian Association for Neuroendocrine Tumors on the management of patients with neuroendocrine neoplasia (NEN) during the pandemic dissemination. METHODS A survey with 57 questions was sent to NEN-dedicated Italian centers regarding the management of patients in the period March 9, 2020, to May 9, 2020 RESULTS: The main modification in the centers' activity consisted of decreases in newly diagnosed NEN patients (- 76.8%), decreases in performed surgical procedures (- 58%), delays to starting peptide receptor radionuclide therapy (45.5%), postponed/canceled follow-up examinations (26%), and canceled multidisciplinary teams' activity (20.8%). A low proportion of centers (< 10%) reported having to withdraw systemic anti-tumor medical treatment due to concerns about the pandemic situation, whereas PRRT was withdrawn from no patients. CONCLUSION Although the COVID-19 outbreak induced the centers to reduce some important activities in the management of NEN patients, the Italian network was able to provide continuity in care without withdrawing anti-tumor treatment for the majority of patients.
Collapse
Affiliation(s)
- F Panzuto
- Digestive Disease Unit, ENETS Center of Excellence, Sant'Andrea University Hospital, Via di Grottarossa 1035, 00189, Rome, Italy.
| | - M Maccauro
- Nuclear Medicine Unit, ENETS Center of Excellence, IRRCS National Cancer Institute (INT), Milan, Italy
| | - D Campana
- Division of Oncology, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
| | - A Faggiano
- Endocrinology Unit, Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy
| | - S Massironi
- Division of Gastroenterology and Center for Autoimmune Liver Diseases, Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy
- European Reference Network on Hepatological Diseases (ERN RARE-LIVER), San Gerardo Hospital, Monza, Italy
| | - S Pusceddu
- Oncology Unit, ENETS Center of Excellence, IRRCS National Cancer Institute (INT), Milan, Italy
| | - F Spada
- Oncology Unit, ENETS Center of Excellence, European Cancer Institute (IEO), Milan, Italy
| | - D Ferone
- Endocrinology Unit, IRCCS Ospedale Policlinico San Martino; Endocrinology, Department of Internal Medicine and Medical Specialties (DIMI), University of Genoa, Genoa, Italy
| | - R Modica
- Department of Clinical Medicine and Surgery, University "Federico II", Naples, Italy
| | - C M Grana
- Nuclear Medicine Division, IRCCS European Institute of Oncology, Milan, Italy
| | - P Ferolla
- Multidisciplinary Group for Diagnosis and Treatment of Neuroendocrine Tumors Umbria Regional Cancer Network, Perugia, Italy
| | - M Rinzivillo
- Digestive Disease Unit, ENETS Center of Excellence, Sant'Andrea University Hospital, Via di Grottarossa 1035, 00189, Rome, Italy
| | - G Badalamenti
- Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy
| | - M C Zatelli
- Section of Endocrinology and Internal Medicine,, Department of Medical Sciences, University of Ferrara, Ferrara, Italy
| | - F Gelsomino
- Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy
| | - E De Carlo
- Department of Medicine, Internal Medicine III, University of Padova, Padua, Italy
| | - M Bartolomei
- Nuclear Medicine Department, Sant'Anna Hospital, Ferrara, Italy
| | - M P Brizzi
- Department of Oncology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Italy
| | - S Cingarlini
- Oncology Unit, ENETS Center of Excellence, University Hospital of Verona, Verona, Italy
| | - A Versari
- Nuclear Medicine Unit, Azienda Unità Sanitaria Locale-IRCCS of Reggio Emilia, Reggio Emilia, Italy
| | - G Fanciulli
- NET Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari - Endocrine Unit, AOU Sassari, Sassari, Italy
| | - E Arvat
- Oncological Endocrinology Unit, Department of Medical Sciences, University of Turin, Turin, Italy
| | - E Merola
- Department of Gastroenterology, Azienda Provinciale per i Servizi Sanitari di Trento (APSS), Trento, Italy
| | - M Cives
- Department of Biomedical Sciences and Human Oncology, University of Bari, Bari, Italy
| | - S Tafuto
- S.C. Sarcomi e Tumori Rari, Istituto Nazionale Tumori, IRCCS Fondazione G. Pascale, Napoli, Italy
| | - S Baldari
- Nuclear Medicine Unit, Department of Biomedical and Dental Sciences and of Morpho-Functional Imaging, University of Messina, Messina, Italy
| | - M Falconi
- Pancreatic Surgery, ENETS Center of Excellence, Pancreas Translational and Clinical Research Center, IRCCS San Raffaele Scientific Institute, Milan, Italy
| |
Collapse
|
7
|
Ricci C, Partelli S, Landoni L, Rinzivillo M, Ingaldi C, Andreasi V, Nessi C, Muffatti F, Fontana M, Tamburrino D, Deiro G, Alberici L, Campana D, Panzuto F, Bassi C, Falconi M, Casadei R. Sporadic non-functioning pancreatic neuroendocrine tumours: multicentre analysis. Br J Surg 2021; 108:811-816. [PMID: 33724300 DOI: 10.1093/bjs/znaa141] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2020] [Revised: 10/05/2020] [Accepted: 11/24/2020] [Indexed: 12/20/2022]
Abstract
BACKGROUND Outcomes after surgery for sporadic pancreatic neuroendocrine neoplasms (Pan-NENs) were evaluated. METHODS This multicentre study included patients who underwent radical pancreatic resection for sporadic non-functioning Pan-NENs. In survival analysis, the risk of mortality in this cohort was analysed in relation to that of the matched healthy Italian population. Relative survival (RS) was calculated as the rate between observed and expected survival. Factors related to RS were investigated using multivariable modelling. RESULTS Among 964 patients who had pancreatic resection for sporadic non-functioning Pan-NENs, the overall RS rate was 91.8 (95 per cent c.i. 81.5 to 96.5) per cent. 2019 WHO grade (hazard ratio (HR) 5.75 (s.e. 4.63); P = 0.030) and European Neuroendocrine Tumour Society (ENETS) TNM stage (6.73 (3.61); P < 0.001) were independent predictors of RS. The probability of a normal lifespan for patients with G1, G2, G3 Pan-NENS, and pancreatic neuroendocrine carcinomas (Pan-NECs) was 96.7, 54.8, 0, and 0 per cent respectively. The probability of a normal lifespan was 99.8, 99.3, 79.8, and 46.8 per cent for those with stage I, II, III, and IV disease respectively. The overall disease-free RS rate was 73.6 (65.2 to 79.5) per cent. 2019 WHO grade (HR 2.10 (0.19); P < 0.001) and ENETS TNM stage (HR 2.50 (0.24); P < 0.001) significantly influenced disease-free RS. The probability of disease-free survival was 93.2, 84.9, 45.2, and 6.8 per cent for patients with stage I, II, III, and IV disease, and 91.9, 45.2, 9.4, and 0.7 per cent for those with G1, G2, G3 Pan-NENS, and Pan-NECs, respectively. CONCLUSION A surgical approach seems without benefit for Pan-NECs, and unnecessary for small G1 sporadic Pan-NENs. Surgery alone may be insufficient for stage III-IV and G3 Pan-NENs.
Collapse
Affiliation(s)
- C Ricci
- Division of Pancreatic Surgery, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.,Department of Internal Medicine and Surgery; Alma Mater Studiorum, University of Bologna, Bologna, Italy
| | - S Partelli
- Pancreatic Surgery Unit, Pancreas Translational and Clinical Research Centre, San Raffaele Scientific Institute, Milan, Italy.,'Vita-Salute' San Raffaele University, Milan, Italy
| | - L Landoni
- General and Pancreatic Surgery Department, Pancreas Institute-University of Verona Hospital Trust, Verona, Italy
| | - M Rinzivillo
- Digestive Disease Unit, ENETS Center of Excellence, Sant'Andrea University Hospital, Rome, Italy
| | - C Ingaldi
- Division of Pancreatic Surgery, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.,Department of Internal Medicine and Surgery; Alma Mater Studiorum, University of Bologna, Bologna, Italy
| | - V Andreasi
- Pancreatic Surgery Unit, Pancreas Translational and Clinical Research Centre, San Raffaele Scientific Institute, Milan, Italy.,'Vita-Salute' San Raffaele University, Milan, Italy
| | - C Nessi
- General and Pancreatic Surgery Department, Pancreas Institute-University of Verona Hospital Trust, Verona, Italy
| | - F Muffatti
- Pancreatic Surgery Unit, Pancreas Translational and Clinical Research Centre, San Raffaele Scientific Institute, Milan, Italy.,'Vita-Salute' San Raffaele University, Milan, Italy
| | - M Fontana
- General and Pancreatic Surgery Department, Pancreas Institute-University of Verona Hospital Trust, Verona, Italy
| | - D Tamburrino
- Pancreatic Surgery Unit, Pancreas Translational and Clinical Research Centre, San Raffaele Scientific Institute, Milan, Italy
| | - G Deiro
- General and Pancreatic Surgery Department, Pancreas Institute-University of Verona Hospital Trust, Verona, Italy
| | - L Alberici
- Division of Pancreatic Surgery, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.,Department of Internal Medicine and Surgery; Alma Mater Studiorum, University of Bologna, Bologna, Italy
| | - D Campana
- Division of Pancreatic Surgery, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.,Division of Oncology, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
| | - F Panzuto
- Digestive Disease Unit, ENETS Center of Excellence, Sant'Andrea University Hospital, Rome, Italy
| | - C Bassi
- General and Pancreatic Surgery Department, Pancreas Institute-University of Verona Hospital Trust, Verona, Italy
| | - M Falconi
- Pancreatic Surgery Unit, Pancreas Translational and Clinical Research Centre, San Raffaele Scientific Institute, Milan, Italy.,'Vita-Salute' San Raffaele University, Milan, Italy
| | - R Casadei
- Division of Pancreatic Surgery, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.,Department of Internal Medicine and Surgery; Alma Mater Studiorum, University of Bologna, Bologna, Italy
| |
Collapse
|
8
|
Massironi S, Campana D, Pusceddu S, Albertelli M, Faggiano A, Panzuto F, Smiroldo V, Andreasi V, Rossi RE, Maggio I, Torchio M, Dotto A, Modica R, Rinzivillo M, Carnaghi C, Partelli S, Fanetti I, Lamberti G, Corti F, Ferone D, Colao A, Annibale B, Invernizzi P, Falconi M. Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: Data from a retrospective multi-centric study. Dig Liver Dis 2021; 53:367-374. [PMID: 33645508 DOI: 10.1016/j.dld.2020.09.031] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/11/2020] [Revised: 09/27/2020] [Accepted: 09/29/2020] [Indexed: 02/08/2023]
Abstract
BACKGROUND Patients with sporadic neuroendocrine neoplasms may exhibit a higher risk of a second primary tumor than the general population. AIM This study aimed to analyze the occurrence of second primary malignancies. METHODS A retrospective cohort of 2757 patients with sporadic lung and gastro-entero-pancreatic neuroendocrine neoplasms, managed at eight Italian tertiary referral Centers, was included. RESULTS Between 2000 and 2019, a second primary malignancy was observed in 271 (9.8%) neuroendocrine neoplasms patients with 32 developing a third tumor. There were 135 (49.8%) females and the median age was 64 years. The most frequent locations of the second tumors were breast (18.8%), prostate (12.5%), colon (9.6%), blood tumors (8.5%), and lung (7.7%). The second primary tumor was synchronous in 19.2% of cases, metachronous in 43.2%, and previous in 37.6%. As concerned the neuroendocrine neoplasms, the 5- and 10-year survival rates were 87.8% and 74.4%, respectively. PFS for patients with a second primary malignancy was shorter than for patients without a second primary malignancy. Death was mainly related to neuroendocrine neoplasms. CONCLUSION In NEN patients the prevalence of second primary malignancies was not negligible, suggesting a possible neoplastic susceptibility. Overall survival was not affected by the occurrence of a second primary malignancy.
Collapse
Affiliation(s)
- S Massironi
- Division Gastroenterology, San Gerardo Hospital, University of Milano - Bicocca School of Medicine, Via Pergolesi 33, 20900 Monza (MB), Italy.
| | - D Campana
- NET Team Bologna, ENETS Center of Excellence, "S. Orsola-Malpighi" University Hospital, "Alma Mater Studiorum" University of Bologna, Bologna, Italy
| | - S Pusceddu
- Department of Medical Oncology, ENETS Center of Excellence, Fondazione IRCCS Istituto Tumori Milano, Milan, Italy
| | - M Albertelli
- Endocrinology Unit, IRCCS Ospedale Policlinico San Martino, and Department of Internal Medicine and Medical Specialties (DiMI), Center of Excellence for Biomedical Research, University of Genova, Genoa, Italy
| | - A Faggiano
- Department of Experimental Medicine, "Sapienza University of Rome" Rome, Italy
| | - F Panzuto
- Digestive Disease Unit, Sant'Andrea University Hospital, ENETS Center of Excellence, Rome, Italy
| | - V Smiroldo
- UO Oncologia Medica ed Ematologia, Humanitas Cancer Center, ENETS Center of Excellence, Humanitas Research Hospital IRCCS, Rozzano, Italy
| | - V Andreasi
- Pancreatic Surgery Unit, ENETS Center of Excellence, Pancreas Translational & Clinical Research Center, San Raffaele Scientific Institute, "Vita-Salute" University, Milan, Italy
| | - R E Rossi
- Gastrointestinal and Hepato-Pancreatic Surgery and Liver Transplantation Unit, ENETS Center of Excellence, Fondazione IRCCS Istituto Nazionale Tumori (INT, National Cancer Institute) and Department of Pathophysiology and Organ Transplant, Università degli Studi di Milano, Milan, Italy
| | - I Maggio
- NET Team Bologna, ENETS Center of Excellence, "S. Orsola-Malpighi" University Hospital, "Alma Mater Studiorum" University of Bologna, Bologna, Italy
| | - M Torchio
- Department of Medical Oncology, ENETS Center of Excellence, Fondazione IRCCS Istituto Tumori Milano, Milan, Italy
| | - A Dotto
- Endocrinology Unit, IRCCS Ospedale Policlinico San Martino, and Department of Internal Medicine and Medical Specialties (DiMI), Center of Excellence for Biomedical Research, University of Genova, Genoa, Italy
| | - R Modica
- Department of Clinical Medicine and Surgery, ENETS Center of Excellence, Federico II University of Naples, Naples, Italy
| | - M Rinzivillo
- Digestive Disease Unit, Sant'Andrea University Hospital, ENETS Center of Excellence, Rome, Italy
| | - C Carnaghi
- UO Oncologia Medica, Comprensorio Sanitario Bolzano, Bozen, Italy
| | - S Partelli
- Pancreatic Surgery Unit, ENETS Center of Excellence, Pancreas Translational & Clinical Research Center, San Raffaele Scientific Institute, "Vita-Salute" University, Milan, Italy
| | - I Fanetti
- Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy
| | - G Lamberti
- NET Team Bologna, ENETS Center of Excellence, "S. Orsola-Malpighi" University Hospital, "Alma Mater Studiorum" University of Bologna, Bologna, Italy
| | - F Corti
- Department of Medical Oncology, ENETS Center of Excellence, Fondazione IRCCS Istituto Tumori Milano, Milan, Italy
| | - D Ferone
- Endocrinology Unit, IRCCS Ospedale Policlinico San Martino, and Department of Internal Medicine and Medical Specialties (DiMI), Center of Excellence for Biomedical Research, University of Genova, Genoa, Italy
| | - A Colao
- Department of Clinical Medicine and Surgery, ENETS Center of Excellence, Federico II University of Naples, Naples, Italy
| | - B Annibale
- Digestive Disease Unit, Sant'Andrea University Hospital, ENETS Center of Excellence, Rome, Italy; Department of Medical-Surgical Sciences and Translational Medicine, "La Sapienza" University of Rome, Rome, Italy
| | - P Invernizzi
- Division Gastroenterology, San Gerardo Hospital, University of Milano - Bicocca School of Medicine, Via Pergolesi 33, 20900 Monza (MB), Italy
| | - M Falconi
- Pancreatic Surgery Unit, ENETS Center of Excellence, Pancreas Translational & Clinical Research Center, San Raffaele Scientific Institute, "Vita-Salute" University, Milan, Italy
| | | |
Collapse
|
9
|
Lamberti G, Maggio I, Manuzzi L, Siepe G, Campana D. 1088P Efficacy of post-operative radiation therapy in non-metastatic Merkel cell carcinoma: A registry-based analysis. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
10
|
Maggio I, Panzuto F, Manuzzi L, Dall'Olio V, Rinzivillo M, Campana D, Lamberti G. 1179P Therapeutic sequences in advanced grade 1-2 pancreatic neuroendocriene tumours (pNET). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1392] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
11
|
Veltroni A, Cosaro E, Spada F, Fazio N, Faggiano A, Colao A, Pusceddu S, Zatelli MC, Campana D, Piovesan A, Pia A, Grossrubatscher EM, Filice A, Bianchi A, Razzore P, Toaiari M, Cingarlini S, Landoni L, Micciolo R, Davì MV. Clinico-pathological features, treatments and survival of malignant insulinomas: a multicenter study. Eur J Endocrinol 2020; 182:439-446. [PMID: 32061159 DOI: 10.1530/eje-19-0989] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/09/2019] [Accepted: 02/12/2020] [Indexed: 11/08/2022]
Abstract
INTRODUCTION Management of malignant insulinomas is challenging due to the need to control both hypoglycaemic syndrome and tumor growth. Literature data is limited to small series. AIM OF THE STUDY To analyze clinico-pathological characteristics, treatments and prognosis of patients with malignant insulinoma. MATERIALS AND METHODS Multicenter retrospective study on 31 patients (male: 61.3%) diagnosed between 1988 and 2017. RESULTS The mean age at diagnosis was 48 years. The mean NET diameter was 41 ± 31 mm, and 70.8% of NETs were G2. Metastases were widespread in 38.7%, hepatic in 41.9% and only lymph nodal in 19.4%. In 16.1% of the cases, the hypoglycaemic syndrome occurred after 46 ± 35 months from the diagnosis of originally non-functioning NET, whereas in 83.9% of the cases it led to the diagnosis of NET, of which 42.3% with a mean diagnostic delay of 32.7 ± 39.8 months. Surgical treatment was performed in 67.7% of the cases. The 5-year survival rate was 62%. Overall survival was significantly higher in patients with Ki-67 ≤10% (P = 0.03), insulin level <60 µU/mL (P = 0.015) and in patients who underwent surgery (P = 0.006). Peptide Receptor Radionuclide Therapy (PRRT) was performed in 45.1%, with syndrome control in 93% of patients. CONCLUSIONS Our study includes the largest series of patients with malignant insulinoma reported to date. The hypoglycaemic syndrome may occur after years in initially non-functioning NETs or be misunderstood with delayed diagnosis of NETs. Surgical treatment and Ki67 ≤10% are prognostic factors associated with better survival. PPRT proved to be effective in the control of hypoglycaemia in majority of cases.
Collapse
Affiliation(s)
- A Veltroni
- Section of Endocrinology, Department of Medicine, ENETS Center of Excellence, Verona University, Verona, Italy
| | - E Cosaro
- Section of Endocrinology, Department of Medicine, ENETS Center of Excellence, Verona University, Verona, Italy
| | - F Spada
- Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, ENETS Center of Excellence, European Institute of Oncology, IEO, IRCCS, Milan, Italy
| | - N Fazio
- Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, ENETS Center of Excellence, European Institute of Oncology, IEO, IRCCS, Milan, Italy
| | - A Faggiano
- Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy
| | - A Colao
- Endocrinology Division, Department of Clinical Medicine and Surgery, ENETS Center of Excellence, University of Naples Federico II, Naples, Italy
| | - S Pusceddu
- Fondazione IRCCS Istituto Nazionale Tumori, ENETS Center of Excellence, Milan, Italy
| | - M C Zatelli
- Section of Endocrinology and Internal Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, Italy
| | - D Campana
- Department of Medical and Surgical Sciences, ENETS Center of Excellence, University of Bologna, Bologna, Italy
| | - A Piovesan
- Oncological Endocrinology Unit, Department of Medical Sciences, University of Turin, Turin, Italy
| | - A Pia
- Internal Medicine, Department of Clinical and Biological Sciences, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Italy
| | - E M Grossrubatscher
- S.C. Endocrinologia ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
| | - A Filice
- Nuclear Medicine Azienda USL-IRCCS Reggio Emilia, Reggio Emilia, Italy
| | - A Bianchi
- Pituitary Unit, Fondazione Policlinico A. Gemelli IRCCS, Catholic University, ENETS Center of Excellence, School of Medicine, Rome, Italy
| | | | - M Toaiari
- Pederzoli Hospital, Peschiera del Garda, Italy
| | - S Cingarlini
- Oncology, ENETS Center of Excellence, University of Verona, Verona, Italy
| | - L Landoni
- Pancreatic Surgery, ENETS Center of Excellence, University of Verona, Verona, Italy
| | - R Micciolo
- Department of Psychology and Cognitive Sciences, University of Trento, Trento, Italy
| | - M V Davì
- Section of Endocrinology, Department of Medicine, ENETS Center of Excellence, Verona University, Verona, Italy
| |
Collapse
|
12
|
Maggio I, Mollica V, Brighi N, Lamberti G, Manuzzi L, Ricci AD, Campana D. The functioning side of the pancreas: a review on insulinomas. J Endocrinol Invest 2020; 43:139-148. [PMID: 31368049 DOI: 10.1007/s40618-019-01091-w] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/18/2019] [Accepted: 07/24/2019] [Indexed: 12/19/2022]
Abstract
PURPOSE Insulinomas are a rare type of neuroendocrine tumors, originating in the pancreas, difficult to diagnose and to treat. Due to its rarity, insulinomas are a not well-known pathological entity; thus, the diagnostic process is frequently a medical challenge with many possible differential diagnoses. The diagnostic process varies between non-invasive procedures, such as the fasting test or imaging techniques, and invasive ones. Insulinomas are rarely malignant, but the glycemic imbalance correlated with this tumor can frequently alter the quality of life of the patients and the consequent hypoglycemia can be extremely dangerous. Moreover, insulinomas can be associated with different genetic syndromes, such as Multiple Endocrine Neoplasia 1, accompanied by other specific symptoms. There are many different treatment strategies, depending on the need to control symptoms or control diseases progression, the only curative one being surgery. METHODS AND RESULTS We reviewed the evidences present in the literature on insulinomas and reported its main clinical characteristics and management strategies. CONCLUSION The aim of this review of the literature is to present the current knowledge on insulinomas, exploring the main clinical characteristics, the diagnostic tools, and the therapeutic strategies.
Collapse
Affiliation(s)
- I Maggio
- Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Alma Mater Studiorum University of Bologna, Via Massarenti 9, 40138, Bologna, Italy
| | - V Mollica
- Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Alma Mater Studiorum University of Bologna, Via Massarenti 9, 40138, Bologna, Italy
| | - N Brighi
- Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Alma Mater Studiorum University of Bologna, Via Massarenti 9, 40138, Bologna, Italy
- NET Team Bologna ENETS Center of Excellence, S. Orsola-Malpighi University Hospital, Alma Mater Studiorum University of Bologna, Via Massarenti 9, 40138, Bologna, Italy
| | - G Lamberti
- Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Alma Mater Studiorum University of Bologna, Via Massarenti 9, 40138, Bologna, Italy
| | - L Manuzzi
- Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Alma Mater Studiorum University of Bologna, Via Massarenti 9, 40138, Bologna, Italy
| | - A D Ricci
- Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Alma Mater Studiorum University of Bologna, Via Massarenti 9, 40138, Bologna, Italy
| | - D Campana
- NET Team Bologna ENETS Center of Excellence, S. Orsola-Malpighi University Hospital, Alma Mater Studiorum University of Bologna, Via Massarenti 9, 40138, Bologna, Italy.
- Department of Medical and Surgical Sciences, S. Orsola-Malpighi University Hospital, Alma Mater Studiorum University of Bologna, Via Massarenti 9, 40138, Bologna, Italy.
| |
Collapse
|
13
|
Cani M, Incorvaia L, Fanale D, De Luca I, Gelsomino F, Ibrahim T, Pusceddu S, Riccardi F, Tafuto S, Lamberti G, Faggiano A, La salvia A, Albertelli M, Massironi S, Rinzivillo M, butturini G, Bazan V, Campana D, Russo A, Badalamenti G. Safety of high doses of somatostatin analogs in well differentiated NENs in elderly. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz245.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
14
|
Marcelli N, Adriani O, Barbarino GC, Bazilevskaya GA, Bellotti R, Boezio M, Bogomolov EA, Bongi M, Bonvicini V, Bottai S, Bruno A, Cafagna F, Campana D, Carlson P, Casolino M, Castellini G, De Santis C, Di Felice V, Galper AM, Karelin A, Koldashov SV, Koldobskiy S, Krutkov SY, Kvashnin AN, Leonov A, Malakhov V, Marcelli L, Martucci M, Mayorov AG, Menn W, Mergè M, Mikhailov VV, Mocchiutti E, Monaco A, Mori N, Munini R, Osteria G, Panico B, Papini P, Pearce M, Picozza P, Ricci M, Ricciarini SB, Simon M, Sparvoli R, Spillantini P, Stozhkov YI, Vacchi A, Vannuccini E, Vasilyev G, Voronov SA, Yurkin YT, Zampa G, Zampa N, Potgieter MS, Aslam OPM, Bisschoff D. Time dependence of the helium flux measured by PAMELA. EPJ Web Conf 2019. [DOI: 10.1051/epjconf/201920901004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Precision measurements of the Z = 2 component in cosmic radiation provide crucial information about the origin and propagation of the second most abundant cosmic ray species in the Galaxy (9% of the total). These measurements, acquired with the PAMELA space experiment orbiting Earth, allow to study solar modulation in details. Helium modulation is compared to the modulation of protons to study possible dependencies on charge and mass. The time dependence of helium fluxes on a monthly basis measured by PAMELA has been studied for the period between July 2006 to January 2016 in the energy range from 800 MeV/n to ~ 20 GeV/n.
Collapse
|
15
|
Yao J, Strosberg J, Fazio N, Pavel M, Ruszniewski P, Bergsland E, Li D, Tafuto S, Raj N, Campana D, Hijioka S, Raderer M, Guimbaud R, Gajate P, Pusceddu S, Reising A, Degtyarev E, Mookerjee B, Aimone P, Singh S. Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy293.001] [Citation(s) in RCA: 41] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
16
|
Bongiovanni A, Pusceddu S, Leo S, Di meglio G, Gelsomino F, Pucci F, Berardi R, Ricci S, Lolli I, Bergamo F, Campana D, Santini D, Tamberi S, Pastorelli D, Cives M, Silvestris N, Russo A, Buonadonna A, Foca F, Ibrahim T. CAPTEM or FOLFIRI as second-line therapy in neuroendocrine carcinomas and exploratory analysis of predictive role of PET imaging and biological markers (SENECA study). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy293.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
17
|
Roessner S, Gross S, Karg M, Hamann A, Campana D, Schuler-Thurner B, Bosch J, Schuler G, Voskens C. 215 Ex vivo expanded NK cells up-regulate natural cytotoxicity receptors able to mediate autologous melanoma cell killing. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.07.212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
18
|
Fazio N, Maisonneuve P, Frezza A, Ibrahim T, La Salvia A, Tafuto S, Pusceddu S, Marconcini R, Silvestris F, Campana D, Santini D, Faggiano A, Massironi S, De Marinis L, Rubini G, Merola E, Antonuzzo L, Amoroso V, Puliafito I, Spada F. Bone metastases in patients with neuroendocrine neoplasms: A survey of natural history and clinical management. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx368.020] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
19
|
Lamberti G, Rossi G, Grillo F, Spada F, Pusceddu S, Rinzivillo M, Massironi S, Tafuto S, Faggiano A, Antonuzzo L, Luppi G, Albertelli M, Fazio N, Vernieri C, Delle Fave G, Brighi N, Ferone D, Campana D. Appendiceal neuroendocrine tumors: a large multicentre Italian series. Preliminary result. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw333.22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
20
|
Adriani O, Barbarino GC, Bazilevskaya GA, Bellotti R, Boezio M, Bogomolov EA, Bongi M, Bonvicini V, Bottai S, Bruno A, Cafagna F, Campana D, Carlson P, Casolino M, Castellini G, De Santis C, Di Felice V, Galper AM, Karelin AV, Koldashov SV, Koldobskiy SA, Krutkov SY, Kvashnin AN, Leonov A, Malakhov V, Marcelli L, Martucci M, Mayorov AG, Menn W, Mergé M, Mikhailov VV, Mocchiutti E, Monaco A, Mori N, Munini R, Osteria G, Panico B, Papini P, Pearce M, Picozza P, Ricci M, Ricciarini SB, Simon M, Sparvoli R, Spillantini P, Stozhkov YI, Vacchi A, Vannuccini E, Vasilyev GI, Voronov SA, Yurkin YT, Zampa G, Zampa N, Potgieter MS, Vos EE. Time Dependence of the Electron and Positron Components of the Cosmic Radiation Measured by the PAMELA Experiment between July 2006 and December 2015. Phys Rev Lett 2016; 116:241105. [PMID: 27367381 DOI: 10.1103/physrevlett.116.241105] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/18/2016] [Indexed: 06/06/2023]
Abstract
Cosmic-ray electrons and positrons are a unique probe of the propagation of cosmic rays as well as of the nature and distribution of particle sources in our Galaxy. Recent measurements of these particles are challenging our basic understanding of the mechanisms of production, acceleration, and propagation of cosmic rays. Particularly striking are the differences between the low energy results collected by the space-borne PAMELA and AMS-02 experiments and older measurements pointing to sign-charge dependence of the solar modulation of cosmic-ray spectra. The PAMELA experiment has been measuring the time variation of the positron and electron intensity at Earth from July 2006 to December 2015 covering the period for the minimum of solar cycle 23 (2006-2009) until the middle of the maximum of solar cycle 24, through the polarity reversal of the heliospheric magnetic field which took place between 2013 and 2014. The positron to electron ratio measured in this time period clearly shows a sign-charge dependence of the solar modulation introduced by particle drifts. These results provide the first clear and continuous observation of how drift effects on solar modulation have unfolded with time from solar minimum to solar maximum and their dependence on the particle rigidity and the cyclic polarity of the solar magnetic field.
Collapse
Affiliation(s)
- O Adriani
- University of Florence, Department of Physics, I-50019 Sesto Fiorentino, Florence, Italy
- INFN, Sezione di Florence, I-50019 Sesto Fiorentino, Florence, Italy
| | - G C Barbarino
- University of Naples "Federico II", Department of Physics, I-80126 Naples, Italy
- INFN, Sezione di Naples, I-80126 Naples, Italy
| | | | - R Bellotti
- University of Bari, Department of Physics, I-70126 Bari, Italy
- INFN, Sezione di Bari, I-70126 Bari, Italy
| | - M Boezio
- INFN, Sezione di Trieste, I-34149 Trieste, Italy
| | - E A Bogomolov
- Ioffe Physical Technical Institute, RU-194021 St. Petersburg, Russia
| | - M Bongi
- University of Florence, Department of Physics, I-50019 Sesto Fiorentino, Florence, Italy
- INFN, Sezione di Florence, I-50019 Sesto Fiorentino, Florence, Italy
| | - V Bonvicini
- INFN, Sezione di Trieste, I-34149 Trieste, Italy
| | - S Bottai
- INFN, Sezione di Florence, I-50019 Sesto Fiorentino, Florence, Italy
| | - A Bruno
- University of Bari, Department of Physics, I-70126 Bari, Italy
- INFN, Sezione di Bari, I-70126 Bari, Italy
| | - F Cafagna
- INFN, Sezione di Bari, I-70126 Bari, Italy
| | - D Campana
- INFN, Sezione di Naples, I-80126 Naples, Italy
| | - P Carlson
- KTH Royal Institute of Technology, Department of Physics, and the Oskar Klein Centre for Cosmoparticle Physics, AlbaNova University Centre, SE-10691 Stockholm, Sweden
| | - M Casolino
- INFN, Sezione di Rome "Tor Vergata", I-00133 Rome, Italy
| | | | - C De Santis
- INFN, Sezione di Rome "Tor Vergata", I-00133 Rome, Italy
- University of Rome "Tor Vergata", Department of Physics, I-00133 Rome, Italy
| | - V Di Felice
- INFN, Sezione di Rome "Tor Vergata", I-00133 Rome, Italy
- Agenzia Spaziale Italiana (ASI) Science Data Center, Via del Politecnico snc, I-00133 Rome, Italy
| | - A M Galper
- National Research Nuclear University MEPhI, RU-115409 Moscow, Russia
| | - A V Karelin
- National Research Nuclear University MEPhI, RU-115409 Moscow, Russia
| | - S V Koldashov
- National Research Nuclear University MEPhI, RU-115409 Moscow, Russia
| | - S A Koldobskiy
- National Research Nuclear University MEPhI, RU-115409 Moscow, Russia
| | - S Y Krutkov
- Ioffe Physical Technical Institute, RU-194021 St. Petersburg, Russia
| | - A N Kvashnin
- Lebedev Physical Institute, RU-119991 Moscow, Russia
| | - A Leonov
- National Research Nuclear University MEPhI, RU-115409 Moscow, Russia
| | - V Malakhov
- National Research Nuclear University MEPhI, RU-115409 Moscow, Russia
| | - L Marcelli
- University of Rome "Tor Vergata", Department of Physics, I-00133 Rome, Italy
| | - M Martucci
- University of Rome "Tor Vergata", Department of Physics, I-00133 Rome, Italy
- INFN, Laboratori Nazionali di Frascati, Via Enrico Fermi 40, I-00044 Frascati, Italy
| | - A G Mayorov
- National Research Nuclear University MEPhI, RU-115409 Moscow, Russia
| | - W Menn
- Universität Siegen, Department of Physics, D-57068 Siegen, Germany
| | - M Mergé
- INFN, Sezione di Rome "Tor Vergata", I-00133 Rome, Italy
- University of Rome "Tor Vergata", Department of Physics, I-00133 Rome, Italy
| | - V V Mikhailov
- National Research Nuclear University MEPhI, RU-115409 Moscow, Russia
| | - E Mocchiutti
- INFN, Sezione di Trieste, I-34149 Trieste, Italy
| | - A Monaco
- University of Bari, Department of Physics, I-70126 Bari, Italy
- INFN, Sezione di Bari, I-70126 Bari, Italy
| | - N Mori
- INFN, Sezione di Florence, I-50019 Sesto Fiorentino, Florence, Italy
| | - R Munini
- INFN, Sezione di Trieste, I-34149 Trieste, Italy
- University of Trieste, Department of Physics, I-34147 Trieste, Italy
| | - G Osteria
- INFN, Sezione di Naples, I-80126 Naples, Italy
| | - B Panico
- INFN, Sezione di Naples, I-80126 Naples, Italy
| | - P Papini
- INFN, Sezione di Florence, I-50019 Sesto Fiorentino, Florence, Italy
| | - M Pearce
- KTH Royal Institute of Technology, Department of Physics, and the Oskar Klein Centre for Cosmoparticle Physics, AlbaNova University Centre, SE-10691 Stockholm, Sweden
| | - P Picozza
- INFN, Sezione di Rome "Tor Vergata", I-00133 Rome, Italy
- University of Rome "Tor Vergata", Department of Physics, I-00133 Rome, Italy
| | - M Ricci
- INFN, Laboratori Nazionali di Frascati, Via Enrico Fermi 40, I-00044 Frascati, Italy
| | - S B Ricciarini
- INFN, Sezione di Florence, I-50019 Sesto Fiorentino, Florence, Italy
| | - M Simon
- Universität Siegen, Department of Physics, D-57068 Siegen, Germany
| | - R Sparvoli
- INFN, Sezione di Rome "Tor Vergata", I-00133 Rome, Italy
- University of Rome "Tor Vergata", Department of Physics, I-00133 Rome, Italy
| | - P Spillantini
- National Research Nuclear University MEPhI, RU-115409 Moscow, Russia
| | - Y I Stozhkov
- Lebedev Physical Institute, RU-119991 Moscow, Russia
| | - A Vacchi
- INFN, Sezione di Trieste, I-34149 Trieste, Italy
- University of Udine, Department of Mathematics and Informatics, I-33100 Udine, Italy
| | - E Vannuccini
- INFN, Sezione di Florence, I-50019 Sesto Fiorentino, Florence, Italy
| | - G I Vasilyev
- Ioffe Physical Technical Institute, RU-194021 St. Petersburg, Russia
| | - S A Voronov
- National Research Nuclear University MEPhI, RU-115409 Moscow, Russia
| | - Y T Yurkin
- National Research Nuclear University MEPhI, RU-115409 Moscow, Russia
| | - G Zampa
- INFN, Sezione di Trieste, I-34149 Trieste, Italy
| | - N Zampa
- INFN, Sezione di Trieste, I-34149 Trieste, Italy
| | - M S Potgieter
- Centre for Space Research, North-West University, 2520 Potchefstroom, South Africa
| | - E E Vos
- Centre for Space Research, North-West University, 2520 Potchefstroom, South Africa
| |
Collapse
|
21
|
Prapa M, Cerioli D, Caldrer S, Spano C, Bestagno M, Golinelli G, Grisendi G, Sardi I, Da Ros M, Iorio A, Bambi F, Paolucci P, Campana D, Dominici M. Adoptive CAR T Cell Therapy Targeting GD2-Positive Cancers. Cytotherapy 2016. [DOI: 10.1016/j.jcyt.2016.03.210] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
22
|
Adriani O, Barbarino GC, Bazilevskaya GA, Bellotti R, Boezio M, Bogomolov EA, Bongi M, Bonvicini V, Bottai S, Bruno A, Cafagna F, Campana D, Carlson P, Casolino M, Castellini G, De Donato C, De Santis C, De Simone N, Di Felice V, Formato V, Galper AM, Karelin AV, Koldashov SV, Koldobskiy S, Krutkov SY, Kvashnin AN, Leonov A, Malakhov V, Marcelli L, Martucci M, Mayorov AG, Menn W, Mergè M, Mikhailov VV, Mocchiutti E, Monaco A, Mori N, Munini R, Osteria G, Palma F, Panico B, Papini P, Pearce M, Picozza P, Ricci M, Ricciarini SB, Sarkar R, Scotti V, Simon M, Sparvoli R, Spillantini P, Stozhkov YI, Vacchi A, Vannuccini E, Vasilyev G, Voronov SA, Yurkin YT, Zampa G, Zampa N. New upper limit on strange quark matter abundance in cosmic rays with the PAMELA space experiment. Phys Rev Lett 2015; 115:111101. [PMID: 26406816 DOI: 10.1103/physrevlett.115.111101] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/10/2015] [Indexed: 06/05/2023]
Abstract
In this work we present results of a direct search for strange quark matter (SQM) in cosmic rays with the PAMELA space spectrometer. If this state of matter exists it may be present in cosmic rays as particles, called strangelets, having a high density and an anomalously high mass-to-charge (A/Z) ratio. A direct search in space is complementary to those from ground-based spectrometers. Furthermore, it has the advantage of being potentially capable of directly identifying these particles, without any assumption on their interaction model with Earth's atmosphere and the long-term stability in terrestrial and lunar rocks. In the rigidity range from 1.0 to ∼1.0×10^{3} GV, no such particles were found in the data collected by PAMELA between 2006 and 2009. An upper limit on the strangelet flux in cosmic rays was therefore set for particles with charge 1≤Z≤8 and mass 4≤A≤1.2×10^{5}. This limit as a function of mass and as a function of magnetic rigidity allows us to constrain models of SQM production and propagation in the Galaxy.
Collapse
Affiliation(s)
- O Adriani
- Department of Physics, University of Florence, I-50019 Sesto Fiorentino, Florence, Italy
- INFN, Sezione di Florence, I-50019 Sesto Fiorentino, Florence, Italy
| | - G C Barbarino
- Department of Physics, University of Naples Federico II, I-80126 Naples, Italy
- INFN, Sezione di Naples, I-80126 Naples, Italy
| | | | - R Bellotti
- Department of Physc,s University of Bari, I-70126 Bari, Italy
- INFN, Sezione di Bari, I-70126 Bari, Italy
| | - M Boezio
- INFN, Sezione di Trieste, I-34149 Trieste, Italy
| | - E A Bogomolov
- Ioffe Physical Technical Institute, RU-194021 St. Petersburg, Russia
| | - M Bongi
- Department of Physics, University of Florence, I-50019 Sesto Fiorentino, Florence, Italy
- INFN, Sezione di Florence, I-50019 Sesto Fiorentino, Florence, Italy
| | - V Bonvicini
- INFN, Sezione di Trieste, I-34149 Trieste, Italy
| | - S Bottai
- INFN, Sezione di Florence, I-50019 Sesto Fiorentino, Florence, Italy
| | - A Bruno
- Department of Physc,s University of Bari, I-70126 Bari, Italy
| | - F Cafagna
- INFN, Sezione di Bari, I-70126 Bari, Italy
| | - D Campana
- INFN, Sezione di Naples, I-80126 Naples, Italy
| | - P Carlson
- Department of Physics, KTH, and the Oskar Klein Centre for Cosmoparticle Physics, AlbaNova University Centre, SE-10691 Stockholm, Sweden
| | - M Casolino
- INFN, Sezione di Rome Tor Vergata, I-00133 Rome, Italy
- RIKEN, Advanced Science Institute, Wako-shi 351-0198, Saitama, Japan
| | | | - C De Donato
- INFN, Sezione di Rome Tor Vergata, I-00133 Rome, Italy
- Department of Physics, University of Rome Tor Vergata, I-00133 Rome, Italy
| | - C De Santis
- INFN, Sezione di Rome Tor Vergata, I-00133 Rome, Italy
| | - N De Simone
- INFN, Sezione di Rome Tor Vergata, I-00133 Rome, Italy
| | - V Di Felice
- INFN, Sezione di Rome Tor Vergata, I-00133 Rome, Italy
- Agenzia Spaziale Italiana (ASI) Science Data Center, I-00044 Frascati, Italy
| | - V Formato
- INFN, Sezione di Trieste, I-34149 Trieste, Italy
- Department of Physics, University of Trieste, I-34147 Trieste, Italy
| | - A M Galper
- National Research Nuclear University MEPhI, RU-115409, Moscow, Russia
| | - A V Karelin
- National Research Nuclear University MEPhI, RU-115409, Moscow, Russia
| | - S V Koldashov
- National Research Nuclear University MEPhI, RU-115409, Moscow, Russia
| | - S Koldobskiy
- National Research Nuclear University MEPhI, RU-115409, Moscow, Russia
| | - S Y Krutkov
- Ioffe Physical Technical Institute, RU-194021 St. Petersburg, Russia
| | - A N Kvashnin
- Lebedev Physical Institute, RU-119991, Moscow, Russia
| | - A Leonov
- National Research Nuclear University MEPhI, RU-115409, Moscow, Russia
| | - V Malakhov
- National Research Nuclear University MEPhI, RU-115409, Moscow, Russia
| | - L Marcelli
- Department of Physics, University of Rome Tor Vergata, I-00133 Rome, Italy
| | - M Martucci
- Department of Physics, University of Rome Tor Vergata, I-00133 Rome, Italy
- INFN, Laboratori Nazionali di Frascati, Via Enrico Fermi 40, I-00044 Frascati, Italy
| | - A G Mayorov
- National Research Nuclear University MEPhI, RU-115409, Moscow, Russia
| | - W Menn
- Department of Physics, Universitat Siegen, D-57068 Siegen, Germany
| | - M Mergè
- INFN, Sezione di Rome Tor Vergata, I-00133 Rome, Italy
- Department of Physics, University of Rome Tor Vergata, I-00133 Rome, Italy
| | - V V Mikhailov
- National Research Nuclear University MEPhI, RU-115409, Moscow, Russia
| | - E Mocchiutti
- INFN, Sezione di Trieste, I-34149 Trieste, Italy
| | - A Monaco
- Department of Physc,s University of Bari, I-70126 Bari, Italy
- INFN, Sezione di Bari, I-70126 Bari, Italy
| | - N Mori
- INFN, Sezione di Florence, I-50019 Sesto Fiorentino, Florence, Italy
- Centro Siciliano di Fisica Nucleare e Struttura della Materia (CSFNSM), Viale A. Doria 6, I-95125 Catania, Italy
| | - R Munini
- INFN, Sezione di Trieste, I-34149 Trieste, Italy
- Department of Physics, University of Trieste, I-34147 Trieste, Italy
| | - G Osteria
- INFN, Sezione di Naples, I-80126 Naples, Italy
| | - F Palma
- INFN, Sezione di Rome Tor Vergata, I-00133 Rome, Italy
- Department of Physics, University of Rome Tor Vergata, I-00133 Rome, Italy
| | - B Panico
- INFN, Sezione di Naples, I-80126 Naples, Italy
| | - P Papini
- INFN, Sezione di Florence, I-50019 Sesto Fiorentino, Florence, Italy
| | - M Pearce
- Department of Physics, KTH, and the Oskar Klein Centre for Cosmoparticle Physics, AlbaNova University Centre, SE-10691 Stockholm, Sweden
| | - P Picozza
- INFN, Sezione di Rome Tor Vergata, I-00133 Rome, Italy
- Department of Physics, University of Rome Tor Vergata, I-00133 Rome, Italy
| | - M Ricci
- INFN, Laboratori Nazionali di Frascati, Via Enrico Fermi 40, I-00044 Frascati, Italy
| | - S B Ricciarini
- INFN, Sezione di Florence, I-50019 Sesto Fiorentino, Florence, Italy
- IFAC, I-50019 Sesto Fiorentino, Florence, Italy
| | - R Sarkar
- Indian Centre for Physics, 43, Chalantika, Garia Station Road, Kolkata 700 084, West Bengal, India
| | - V Scotti
- Department of Physics, University of Naples Federico II, I-80126 Naples, Italy
- INFN, Sezione di Naples, I-80126 Naples, Italy
| | - M Simon
- Department of Physics, Universitat Siegen, D-57068 Siegen, Germany
| | - R Sparvoli
- INFN, Sezione di Rome Tor Vergata, I-00133 Rome, Italy
- Department of Physics, University of Rome Tor Vergata, I-00133 Rome, Italy
| | - P Spillantini
- Department of Physics, University of Florence, I-50019 Sesto Fiorentino, Florence, Italy
- INFN, Sezione di Florence, I-50019 Sesto Fiorentino, Florence, Italy
| | - Y I Stozhkov
- Lebedev Physical Institute, RU-119991, Moscow, Russia
| | - A Vacchi
- INFN, Sezione di Trieste, I-34149 Trieste, Italy
| | - E Vannuccini
- INFN, Sezione di Florence, I-50019 Sesto Fiorentino, Florence, Italy
| | - G Vasilyev
- Ioffe Physical Technical Institute, RU-194021 St. Petersburg, Russia
| | - S A Voronov
- National Research Nuclear University MEPhI, RU-115409, Moscow, Russia
| | - Y T Yurkin
- National Research Nuclear University MEPhI, RU-115409, Moscow, Russia
| | - G Zampa
- INFN, Sezione di Trieste, I-34149 Trieste, Italy
| | - N Zampa
- INFN, Sezione di Trieste, I-34149 Trieste, Italy
| |
Collapse
|
23
|
Adriani O, Barbarino GC, Bazilevskaya GA, Bellotti R, Boezio M, Bogomolov EA, Bongi M, Bonvicini V, Bottai S, Bruno A, Cafagna F, Campana D, Carlson P, Casolino M, Castellini G, Donato CD, Santis CD, Simone ND, Felice VD, Formato V, Galper AM, Karelin AV, Koldashov SV, Koldobskiy S, Krutkov SY, Kvashnin AN, Leonov A, Malakhov V, Marcelli L, Martucci M, Mayorov AG, Menn W, Mergè M, Mikhailov VV, Mocchiutti E, Monaco A, Mori N, Munini R, Osteria G, Palma F, Panico B, Papini P, Pearce M, Picozza P, Ricci M, Ricciarini SB, Sarkar R, Scotti V, Simon M, Sparvoli R, Spillantini P, Stozhkov YI, Vacchi A, Vannuccini E, Vasilyev G, Voronov SA, Yurkin YT, Zampa G, Zampa N, Potgieter MS, Vos EE. TIME DEPENDENCE OF THEe−FLUX MEASURED BYPAMELADURING THE 2006 JULY–2009 DECEMBER SOLAR MINIMUM. ACTA ACUST UNITED AC 2015. [DOI: 10.1088/0004-637x/810/2/142] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
24
|
Adriani O, Barbarino GC, Bazilevskaya GA, Bellotti R, Boezio M, Bogomolov EA, Bongi M, Bonvicini V, Bottai S, Bruno A, Cafagna F, Campana D, Carbone R, Carlson P, Casolino M, Castellini G, De Donato C, De Santis C, De Simone N, Felice VD, Formato V, Galper AM, Karelin AV, Koldashov SV, Koldobskiy S, Krutkov SY, Kvashnin AN, Leonov A, Malakhov V, Marcelli L, Martucci M, Mayorov AG, Menn W, Mergé M, Mikhailov VV, Mocchiutti E, Monaco A, Mori N, Munini R, Osteria G, Palma F, Panico B, Papini P, Pearce M, Picozza P, Ricci M, Ricciarini SB, Sarkar R, Scotti V, Simon M, Sparvoli R, Spillantini P, Stozhkov YI, Vacchi A, Vannuccini E, Vasilyev GI, Voronov SA, Yurkin YT, Zampa G, Zampa N, Zverev VG. TRAPPED PROTON FLUXES AT LOW EARTH ORBITS MEASURED BY THE
PAMELA
EXPERIMENT. ACTA ACUST UNITED AC 2015. [DOI: 10.1088/2041-8205/799/1/l4] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
25
|
Adriani O, Barbarino GC, Bazilevskaya GA, Bellotti R, Boezio M, Bogomolov EA, Bongi M, Bonvicini V, Bottai S, Bruno A, Cafagna F, Campana D, Carbone R, Carlson P, Casolino M, Castellini G, Danilchenko IA, De Donato C, De Santis C, De Simone N, Felice VD, Formato V, Galper AM, Karelin AV, Koldashov SV, Koldobskiy S, Krutkov SY, Kvashnin AN, Leonov A, Malakhov V, Marcelli L, Martucci M, Mayorov AG, Menn W, Mergé M, Mikhailov VV, Mocchiutti E, Monaco A, Mori N, Munini R, Osteria G, Palma F, Panico B, Papini P, Pearce M, Picozza P, Pizzolotto C, Ricci M, Ricciarini SB, Rossetto L, Sarkar R, Scotti V, Simon M, Sparvoli R, Spillantini P, Stozhkov YI, Vacchi A, Vannuccini E, Vasilyev GI, Voronov SA, Yurkin YT, Zampa G, Zampa N, Zverev VG. MEASUREMENT OF BORON AND CARBON FLUXES IN COSMIC RAYS WITH THE PAMELA EXPERIMENT. ACTA ACUST UNITED AC 2014. [DOI: 10.1088/0004-637x/791/2/93] [Citation(s) in RCA: 115] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
26
|
Pui CH, Pei D, Campana D, Cheng C, Sandlund JT, Bowman WP, Hudson MM, Ribeiro RC, Raimondi SC, Jeha S, Howard SC, Bhojwani D, Inaba H, Rubnitz JE, Metzger ML, Gruber TA, Coustan-Smith E, Downing JR, Leung WH, Relling MV, Evans WE. A revised definition for cure of childhood acute lymphoblastic leukemia. Leukemia 2014; 28:2336-43. [PMID: 24781017 PMCID: PMC4214904 DOI: 10.1038/leu.2014.142] [Citation(s) in RCA: 90] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2014] [Accepted: 04/11/2014] [Indexed: 12/22/2022]
Abstract
With improved contemporary therapy, we re-assess long-term outcome in patients completing treatment for childhood acute lymphoblastic leukemia to determine when cure can be declared with a high degree of confidence. In 6 successive clinical trials between 1984 and 2007, 1291(84.5%) patients completed all therapy in continuous complete remission. The post-therapy cumulative risk of relapse or development of a second neoplasm and the event-free survival rate and overall survival were analyzed according to the presenting features and the three treatment periods defined by relative outcome. Over the three treatment periods, there has been progressive increase in the rate of event-free survival (65.2% vs. 74.8% vs. 85.1% [P<0.001]) and overall survival (76.5% vs. 81.1% vs. 91.7% [P<0.001]) at 10 years. The most important predictor of outcome after completion of therapy was the type of treatment. In the most recent treatment period, which omitted the use of prophylactic cranial irradiation, the post-treatment cumulative risk of relapse was 6.4%, death in remission 1.5%, and development of a second neoplasm 2.3% at 10 years, with all relapses except one occurring within 4 years off therapy. None of the 106 patients with the t(9;22)/BCR-ABL1, t(1;19)/TCF3-PBX1 or t(4;11)/MLL-AFF1 had relapsed after 2 years from completion of therapy. These findings demonstrate that with contemporary effective therapy that excludes cranial irradiation, approximately 6% of children with acute lymphoblastic leukemia may relapse after completion of treatment, and those who remain in remission at 4 years post-treatment may be considered cured (i.e., less than 1 % chance of relapse).
Collapse
Affiliation(s)
- C H Pui
- 1] Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA [2] Department of Pathology, St Jude Children's Research Hospital, Memphis, TN, USA
| | - D Pei
- Department of Biostatistics, St Jude Children's Research Hospital, Memphis, TN, USA
| | - D Campana
- Centre for Translational Medicine, National University of Singapore, Singapore, Singapore
| | - C Cheng
- Department of Biostatistics, St Jude Children's Research Hospital, Memphis, TN, USA
| | - J T Sandlund
- Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA
| | - W P Bowman
- Department of Pediatrics, University of North Texas Health Science Center, Fort Worth, TX, USA
| | - M M Hudson
- Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA
| | - R C Ribeiro
- Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA
| | - S C Raimondi
- Department of Pathology, St Jude Children's Research Hospital, Memphis, TN, USA
| | - S Jeha
- Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA
| | - S C Howard
- Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA
| | - D Bhojwani
- Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA
| | - H Inaba
- Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA
| | - J E Rubnitz
- Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA
| | - M L Metzger
- Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA
| | - T A Gruber
- Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA
| | - E Coustan-Smith
- Centre for Translational Medicine, National University of Singapore, Singapore, Singapore
| | - J R Downing
- Department of Pathology, St Jude Children's Research Hospital, Memphis, TN, USA
| | - W H Leung
- Department of Bone Marrow Transplantation and Cellular Therapy, St Jude Children's Research Hospital, Memphis, TN, USA
| | - M V Relling
- Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, TN, USA
| | - W E Evans
- Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, TN, USA
| |
Collapse
|
27
|
Ricciarini SB, Adriani O, Barbarino G, Bazilevskaya G, Bellotti R, Boezio M, Bogomolov E, Bongi M, Bonvicini V, Bottai S, Bruno A, Cafagna F, Campana D, Carbone R, Carlson P, Casolino M, Castellini G, De Donato C, De Pascale M, De Santis C, De Simone N, Di Felice V, Formato V, Galper A, Karelin A, Kheymits M, Koldashov S, Koldobskiy S, Krutkov S, Kvashnin A, Leonov A, Malakhov V, Marcelli L, Martucci M, Mayorov A, Menn W, Mergè M, Mikhailov V, Mocchiutti E, Monaco A, Mori N, Munini R, Osteria G, Palma F, Panico B, Papini P, Pearce M, Picozza P, Pizzolotto C, Ricci M, Sarkar R, Simon M, Scotti V, Sparvoli R, Spillantini P, Stozhkov Y, Vacchi A, Vannuccini E, Vasilyev G, Voronov S, Yurkin Y, Zampa G, Zampa N, Zverev V. PAMELA mission: heralding a new era in cosmic ray physics. EPJ Web of Conferences 2014. [DOI: 10.1051/epjconf/20147100115] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
28
|
Adriani O, Barbarino GC, Bazilevskaya GA, Bellotti R, Bianco A, Boezio M, Bogomolov EA, Bongi M, Bonvicini V, Bottai S, Bruno A, Cafagna F, Campana D, Carbone R, Carlson P, Casolino M, Castellini G, De Donato C, De Santis C, De Simone N, Di Felice V, Formato V, Galper AM, Karelin AV, Koldashov SV, Koldobskiy SA, Krutkov SY, Kvashnin AN, Leonov A, Malakhov V, Marcelli L, Martucci M, Mayorov AG, Menn W, Mergé M, Mikhailov VV, Mocchiutti E, Monaco A, Mori N, Munini R, Osteria G, Palma F, Papini P, Pearce M, Picozza P, Pizzolotto C, Ricci M, Ricciarini SB, Rossetto L, Sarkar R, Scotti V, Simon M, Sparvoli R, Spillantini P, Stochaj SJ, Stockton JC, Stozhkov YI, Vacchi A, Vannuccini E, Vasilyev GI, Voronov SA, Yurkin YT, Zampa G, Zampa N, Zverev VG. Cosmic-ray positron energy spectrum measured by PAMELA. Phys Rev Lett 2013; 111:081102. [PMID: 24010424 DOI: 10.1103/physrevlett.111.081102] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/19/2013] [Indexed: 06/02/2023]
Abstract
Precision measurements of the positron component in the cosmic radiation provide important information about the propagation of cosmic rays and the nature of particle sources in our Galaxy. The satellite-borne experiment PAMELA has been used to make a new measurement of the cosmic-ray positron flux and fraction that extends previously published measurements up to 300 GeV in kinetic energy. The combined measurements of the cosmic-ray positron energy spectrum and fraction provide a unique tool to constrain interpretation models. During the recent solar minimum activity period from July 2006 to December 2009, approximately 24,500 positrons were observed. The results cannot be easily reconciled with purely secondary production, and additional sources of either astrophysical or exotic origin may be required.
Collapse
Affiliation(s)
- O Adriani
- Department of Physics, University of Florence, I-50019 Sesto Fiorentino, Florence, Italy and INFN, Sezione di Florence, I-50019 Sesto Fiorentino, Florence, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Sandlund JT, Pui CH, Zhou Y, Onciu M, Campana D, Hudson MM, Inaba H, Metzger ML, Bhojwani D, Ribeiro RC. Results of treatment of advanced-stage lymphoblastic lymphoma at St Jude Children's Research Hospital from 1962 to 2002. Ann Oncol 2013; 24:2425-9. [PMID: 23788752 DOI: 10.1093/annonc/mdt221] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Reliable prognostic factors have not been established for advanced-stage pediatric lymphoblastic lymphoma (LL). We analyzed treatment outcomes and potential risk factors in children and adolescents with advanced-stage LL treated over a 40-year period. PATIENTS AND METHODS From 1962 through 2002, 146 patients (99 boys and 47 girls) with stage III (n = 111) or stage IV (n = 35) LL were treated at St Jude Children's Research Hospital. The five treatment eras were 1962-1975 (no protocol), 1975-1979 (NHL-75), 1979-1984 (Total 10 High), 1985-1992 (Pediatric Oncology Group protocol), and 1992-2002 (NHL13). Age at diagnosis was <10 years in 65 patients and ≥10 years in 81. RESULTS Outcomes improved markedly over successive treatment eras. NHL13 produced the highest 5-year event-free survival (EFS) estimate (82.9% ± 6.1% [SE]) compared with only 20.0% ± 8.0% during the earliest era. Treatment era (P < 0.0001) and age at diagnosis (<10 years versus ≥10 years, P = 0.0153) were independent prognostic factors, whereas disease stage, lactate dehydrogenase level, and presence of a pleural effusion were not. CONCLUSIONS Treatment era and age were the most important prognostic factors for children with advanced-stage LL. We suggest that a better assessment of early treatment response may help to identify patients with drug-resistant disease who require more intensive therapy.
Collapse
Affiliation(s)
- J T Sandlund
- Department of Oncology, St Jude Children’s Research Hospital, TN 38105-3678, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Faggiano A, Ferolla P, Grimaldi F, Campana D, Manzoni M, Davì MV, Bianchi A, Valcavi R, Papini E, Giuffrida D, Ferone D, Fanciulli G, Arnaldi G, Franchi GM, Francia G, Fasola G, Crinò L, Pontecorvi A, Tomassetti P, Colao A. Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study. J Endocrinol Invest 2012; 35:817-23. [PMID: 22080849 DOI: 10.3275/8102] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
BACKGROUND The few epidemiological data available in literature on neuroendocrine tumors (NET) are mainly based on Registry databases, missing therefore details on their clinical and natural history. AIM To investigate epidemiology, clinical presentation, and natural history of NET. DESIGN AND SETTING A large national retrospective survey was conducted in 13 Italian referral centers. Among 1203 NET, 820 originating in the thorax (T-NET), in the gastro-enteropancreatic tract (GEP-NET) or metastatic NET of unknown primary origin (U-NET) were enrolled in the study. RESULTS 93% had a sporadic and 7% a multiple endocrine neoplasia type 1 (MEN1)-associated tumor; 63% were GEP-NET, 33% T-NET, 4% U-NET. Pancreas and lung were the commonest primary sites. Poorly differentiated carcinomas were <10%, all sporadic. The incidence of NET had a linear increase from 1990 to 2007 in all the centers. The mean age at diagnosis was 60.0 ± 16.4 yr, significantly anticipated in MEN1 patients (47.7 ± 16.5 yr). Association with cigarette smoking and other non-NET cancer were more prevalent than in the general Italian population. The first symptoms of the disease were related to tumor burden in 46%, endocrine syndrome in 23%, while the diagnosis was fortuity in 29%. Insulin (37%) and serotonin (35%) were the most common hormonal hypersecretions. An advanced tumor stage was found in 42%, more frequently in the gut and thymus. No differences in the overall survival was observed between T-NET and GEP-NET and between sporadic and MEN1-associated tumors at 10 yr from diagnosis, while survival probability was dramatically reduced in U-NET. CONCLUSIONS The data obtained from this study furnish relevant information on epidemiology, natural history, and clinico-pathological features of NET, not available from the few published Register studies.
Collapse
Affiliation(s)
- A Faggiano
- Department of Molecular and Clinical Endocrinology and Oncology, Section of Endocrinology, University of Naples "Federico II", Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Abstract
The aim of minimal residual disease (MRD) studies in patients with acute leukemia is to measure initial treatment response accurately, provide an assessment of the residual leukemic burden throughout therapy and detect relapse early. Therefore, information resulting from MRD monitoring can substantially improve many facets of clinical management. Methods for MRD detection, namely flow cytometry and PCR, have been applied to study the remission status of thousands of patients with acute lymphoblastic leukemia and acute myeloid leukemia. Collectively, the data indicate that MRD is a powerful prognostic indicator and an indispensable parameter for risk-adapted therapy. The current status of MRD in acute leukemia is briefly reviewed in this paper.
Collapse
Affiliation(s)
- D Campana
- Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Centre for Translational Medicine , Singapore, Singapore
| |
Collapse
|
32
|
Abstract
Natural killer (NK) cells can kill transformed cells and represent a promising tool for the treatment of cancer. Their function is governed by a balance of stimulatory and inhibitory signals triggered by surface receptors. Advances in NK cell therapy require the development of dependable methods for obtaining an adequate number of effector cells; additional activation or genetic modification may further increase their anticancer capacity. A method for NK cell expansion used in our laboratory relies on a genetically modified form of the K562 myeloid leukemia cell line, engineered to express a membrane-bound form of interleukin-15 and the ligand for the costimulatory molecule 4-1BB (CD137). Expanded NK cells can be transduced with genes encoding chimeric antigen receptors that stimulate tumor cell-specific cytotoxicity. These methods for NK cell expansion and genetic modification have been adapted to large-scale, clinical-grade, Current Good Manufacturing Practice conditions and support two active clinical trials. Summarized are current efforts for NK cell immunotherapy for cancer and future perspectives.
Collapse
Affiliation(s)
- D R Shook
- Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA.
| | | |
Collapse
|
33
|
Bhojwani D, Pei D, Sandlund JT, Jeha S, Ribeiro RC, Rubnitz JE, Raimondi SC, Shurtleff S, Onciu M, Cheng C, Coustan-Smith E, Bowman WP, Howard SC, Metzger ML, Inaba H, Leung W, Evans WE, Campana D, Relling MV, Pui CH. ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy. Leukemia 2012; 26:265-70. [PMID: 21869842 PMCID: PMC3345278 DOI: 10.1038/leu.2011.227] [Citation(s) in RCA: 82] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2011] [Revised: 06/30/2011] [Accepted: 07/20/2011] [Indexed: 11/08/2022]
Abstract
ETV6-RUNX1 fusion is the most common genetic aberration in childhood acute lymphoblastic leukemia (ALL). To evaluate whether outcomes for this drug-sensitive leukemia are improved by contemporary risk-directed therapy, we studied clinical features, response and adverse events of 168 children with newly diagnosed ETV6-RUNX1-positive ALL on St Jude Total Therapy studies XIIIA (N=36), XIIIB (N=38) and XV (N=94). Results were compared with 494 ETV6-RUNX1-negative B-precursor ALL patients. ETV6-RUNX1 was associated with age 1-9 years, pre-treatment classification as low risk and lower levels of minimal residual disease (MRD) on day 19 of therapy (P<0.001). Event-free survival (EFS) or overall survival (OS) did not differ between patients with or without ETV6-RUNX1 in Total XIIIA or XIIIB. By contrast, in Total XV, patients with ETV6-RUNX1 had significantly better EFS (P=0.04; 5-year estimate, 96.8±2.4% versus 88.3±2.5%) and OS (P=0.04; 98.9±1.4% versus 93.7±1.8%) than those without ETV6-RUNX1. Within the ETV6-RUNX1 group, the only significant prognostic factor associated with higher OS was the treatment protocol Total XV (versus XIIIA or XIIIB) (P=0.01). Thus, the MRD-guided treatment schema including intensive asparaginase and high-dose methotrexate in the Total XV study produced significantly better outcomes than previous regimens and demonstrated that nearly all children with ETV6-RUNX1 ALL can be cured.
Collapse
Affiliation(s)
- D Bhojwani
- Department of Oncology, St Jude Children's Research Hospital, Memphis, TN 38105, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Adriani O, Barbarino GC, Bazilevskaya GA, Bellotti R, Boezio M, Bogomolov EA, Bongi M, Bonvicini V, Borisov S, Bottai S, Bruno A, Cafagna F, Campana D, Carbone R, Carlson P, Casolino M, Castellini G, Consiglio L, De Pascale MP, De Santis C, De Simone N, Di Felice V, Galper AM, Gillard W, Grishantseva L, Jerse G, Karelin AV, Koldashov SV, Krutkov SY, Kvashnin AN, Leonov A, Malakhov V, Malvezzi V, Marcelli L, Mayorov AG, Menn W, Mikhailov VV, Mocchiutti E, Monaco A, Mori N, Nikonov N, Osteria G, Palma F, Papini P, Pearce M, Picozza P, Pizzolotto C, Ricci M, Ricciarini SB, Rossetto L, Sarkar R, Simon M, Sparvoli R, Spillantini P, Stochaj SJ, Stockton JC, Stozhkov YI, Vacchi A, Vannuccini E, Vasilyev G, Voronov SA, Wu J, Yurkin YT, Zampa G, Zampa N, Zverev VG. Cosmic-ray electron flux measured by the PAMELA experiment between 1 and 625 GeV. Phys Rev Lett 2011; 106:201101. [PMID: 21668214 DOI: 10.1103/physrevlett.106.201101] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/23/2010] [Indexed: 05/30/2023]
Abstract
Precision measurements of the electron component in the cosmic radiation provide important information about the origin and propagation of cosmic rays in the Galaxy. Here we present new results regarding negatively charged electrons between 1 and 625 GeV performed by the satellite-borne experiment PAMELA. This is the first time that cosmic-ray e⁻ have been identified above 50 GeV. The electron spectrum can be described with a single power-law energy dependence with spectral index -3.18 ± 0.05 above the energy region influenced by the solar wind (> 30 GeV). No significant spectral features are observed and the data can be interpreted in terms of conventional diffusive propagation models. However, the data are also consistent with models including new cosmic-ray sources that could explain the rise in the positron fraction.
Collapse
Affiliation(s)
- O Adriani
- University of Florence, Department of Physics, I-50019 Sesto Fiorentino, Florence, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Adriani O, Barbarino GC, Bazilevskaya GA, Bellotti R, Boezio M, Bogomolov EA, Bonechi L, Bongi M, Bonvicini V, Borisov S, Bottai S, Bruno A, Cafagna F, Campana D, Carbone R, Carlson P, Casolino M, Castellini G, Consiglio L, De Pascale MP, De Santis C, De Simone N, Di Felice V, Galper AM, Gillard W, Grishantseva L, Jerse G, Karelin AV, Koldashov SV, Krutkov SY, Kvashnin AN, Leonov A, Malakhov V, Malvezzi V, Marcelli L, Mayorov AG, Menn W, Mikhailov VV, Mocchiutti E, Monaco A, Mori N, Nikonov N, Osteria G, Palma F, Papini P, Pearce M, Picozza P, Pizzolotto C, Ricci M, Ricciarini SB, Rossetto L, Sarkar R, Simon M, Sparvoli R, Spillantini P, Stozhkov YI, Vacchi A, Vannuccini E, Vasilyev G, Voronov SA, Yurkin YT, Wu J, Zampa G, Zampa N, Zverev VG. PAMELA Measurements of Cosmic-Ray Proton and Helium Spectra. Science 2011; 332:69-72. [DOI: 10.1126/science.1199172] [Citation(s) in RCA: 593] [Impact Index Per Article: 45.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
36
|
Luszczek W, Morales-Tirado V, Woolard S, Van Der Merwe M, Shook D, Campana D, Pillai A. Expanded Human INKT Cells Exhibit Th2 Polarization and Direct Cytotoxicity Against Hematolymphoid Tumor Targets. Biol Blood Marrow Transplant 2011. [DOI: 10.1016/j.bbmt.2010.12.188] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
37
|
Adriani O, Barbarino GC, Bazilevskaya GA, Bellotti R, Boezio M, Bogomolov EA, Bonechi L, Bongi M, Bonvicini V, Borisov S, Bottai S, Bruno A, Cafagna F, Campana D, Carbone R, Carlson P, Casolino M, Castellini G, Consiglio L, De Pascale MP, De Santis C, De Simone N, Di Felice V, Galper AM, Gillard W, Grishantseva L, Hofverberg P, Jerse G, Karelin AV, Koldashov SV, Krutkov SY, Kvashnin AN, Leonov A, Malvezzi V, Marcelli L, Mayorov AG, Menn W, Mikhailov VV, Mocchiutti E, Monaco A, Mori N, Nikonov N, Osteria G, Papini P, Pearce M, Picozza P, Pizzolotto C, Ricci M, Ricciarini SB, Rossetto L, Simon M, Sparvoli R, Spillantini P, Stozhkov YI, Vacchi A, Vannuccini E, Vasilyev G, Voronov SA, Wu J, Yurkin YT, Zampa G, Zampa N, Zverev VG. PAMELA results on the cosmic-ray antiproton flux from 60 MeV to 180 GeV in kinetic energy. Phys Rev Lett 2010; 105:121101. [PMID: 20867623 DOI: 10.1103/physrevlett.105.121101] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/03/2010] [Indexed: 05/29/2023]
Abstract
The satellite-borne experiment PAMELA has been used to make a new measurement of the cosmic-ray antiproton flux and the antiproton-to-proton flux ratio which extends previously published measurements down to 60 MeV and up to 180 GeV in kinetic energy. During 850 days of data acquisition approximately 1500 antiprotons were observed. The measurements are consistent with purely secondary production of antiprotons in the Galaxy. More precise secondary production models are required for a complete interpretation of the results.
Collapse
Affiliation(s)
- O Adriani
- University of Florence, Department of Physics, I-50019 Sesto Fiorentino, Florence, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Rinzivillo M, Capurso G, Campana D, Fazio N, Panzuto F, Bestani C, Merola E, Falconi M, Tomassetti P, delle Fave G. Risk and protective factors for midgut carcinoid tumors: Multicenter case-control study of prospectively evaluated patients. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e14533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
39
|
Pui CH, Pei D, Sandlund JT, Ribeiro RC, Rubnitz JE, Raimondi SC, Onciu M, Campana D, Kun LE, Jeha S, Cheng C, Howard SC, Metzger ML, Bhojwani D, Downing JR, Evans WE, Relling MV. Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia 2010; 24:371-82. [PMID: 20010620 PMCID: PMC2820159 DOI: 10.1038/leu.2009.252] [Citation(s) in RCA: 224] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2009] [Accepted: 08/06/2009] [Indexed: 02/08/2023]
Abstract
We analyzed the long-term outcome of 1011 patients treated in five successive clinical trials (Total Therapy Studies 11, 12, 13A, 13B, and 14) between 1984 and 1999. The event-free survival improved significantly (P=0.003) from the first two trials conducted in the 1980s to the three more recent trials conducted in the 1990s. Approximately 75% of patients treated in the 1980s and 80% in the 1990s were cured. Early intensive triple intrathecal therapy, together with more effective systemic therapy, including consolidation and reinduction treatment (Studies 13A and 13B) as well as dexamethasone (Study 13B), resulted in a very low rate of isolated central nervous system (CNS) relapse rate (<2%), despite the reduced use of cranial irradiation. Factors consistently associated with treatment outcome were age, leukocyte count, immunophenotype, DNA index, and minimal residual disease level after remission induction treatment. Owing to concerns about therapy-related secondary myeloid leukemia and brain tumors, in our current trials we reserve the use of etoposide for patients with refractory or relapsed leukemia undergoing hematopoietic stem cell transplantation, and cranial irradiation for those with CNS relapse. The next main challenge is to further increase cure rates while improving quality of life for all patients.
Collapse
Affiliation(s)
- C H Pui
- Department of Oncology, St Jude Children's Research Hospital, Memphis, TN 38105, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Li L, Liu LN, Feller S, Allen C, Shivakumar R, Fratantoni J, Wolfraim LA, Fujisaki H, Campana D, Chopas N, Dzekunov S, Peshwa M. Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method. Cancer Gene Ther 2009; 17:147-54. [PMID: 19745843 DOI: 10.1038/cgt.2009.61] [Citation(s) in RCA: 107] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Natural killer (NK) cells hold promise for cancer therapy. NK cytotoxicity can be enhanced by expression of chimeric antigen receptors that re-direct specificity toward target cells by engaging cell surface molecules expressed on target cells. We developed a regulatory-compliant, scalable non-viral approach to engineer NK cells to be target-specific based on transfection of mRNA encoding chimeric receptors. Transfection of eGFP mRNA into ex vivo expanded NK cells (N=5) or purified unstimulated NK cells from peripheral blood (N=4) resulted in good cell viability with eGFP expression in 85+/-6% and 86+/-4%, 24 h after transfection, respectively. An mRNA encoding a receptor directed against CD19 (anti-CD19-BB-z) was also transfected into NK cells efficiently. Ex vivo expanded and purified unstimulated NK cells expressing anti-CD19-BB-z exhibited enhanced cytotoxicity against CD19(+) target cells resulting in > or =80% lysis of acute lymphoblastic leukemia and B-lineage chronic lymphocytic leukemia cells at effector target ratios lower than 10:1. The target-specific cytotoxicity for anti-CD19-BB-z mRNA-transfected NK cells was observed as early as 3 h after transfection and persisted for up to 3 days. The method described here should facilitate the clinical development of NK-based antigen-targeted immunotherapy for cancer.
Collapse
Affiliation(s)
- L Li
- MaxCyte Inc, Gaithersburg, MD 20878, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Pezzilli R, Morselli-Labate AM, Campana D, Casadei R, Brocchi E, Corinaldesi R. Evaluation of patient-reported outcome in subjects treated medically for acute pancreatitis: a follow-up study. Pancreatology 2009; 9:375-82. [PMID: 19451747 DOI: 10.1159/000181171] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/08/2008] [Accepted: 10/29/2008] [Indexed: 12/11/2022]
Abstract
AIMS To explore the quality of life in patients treated medically during the acute phase of pancreatitis as well as at 2 and 12 months after discharge from the hospital. PATIENTS 40 patients were studied. The etiology of the pancreatitis was biliary causes in 31 patients and non-biliary causes in 9; mild disease was present in 29 patients and severe disease in 11. 30 patients completed the two surveys at 2 and 12 months after hospital discharge. METHODS The SF-12 and EORTC QLQ-C30 questionnaires were used for the purpose of the study. RESULTS The two physical and mental component summaries of SF-12, all the domains of EORTC QLQ-C30 (except for physical functioning and cognitive functioning) and some symptom scales of EORTC QLQ-C30 (fatigue, nausea/vomiting, pain, and constipation) were significantly impaired during the acute phase of pancreatitis. There was a significant improvement in the SF-12 physical component summary, and global health, role functioning, social functioning, nausea/vomiting, pain, dyspnea, and financial difficulties (EORTC QLQ-C30) at 2 months after discharge as compared to the basal evaluation. Similar results were found after 12 months except for the mental component score at 12-month evaluation, which was significantly impaired in acute pancreatitis patients in comparison to the norms. The physical functioning of the EORTC QLQ-C30 at basal evaluation was significantly impaired in patients with severe pancreatitis in comparison to patients with mild pancreatitis. CONCLUSIONS Two different patterns can be recognized in the quality of life of patients with acute pancreatitis: physical impairment is immediately present followed by mental impairment which appears progressively in the follow-up period.
Collapse
Affiliation(s)
- R Pezzilli
- Department of Digestive Diseases and Internal Medicine, Sant'Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
| | | | | | | | | | | |
Collapse
|
42
|
Adriani O, Barbarino GC, Bazilevskaya GA, Bellotti R, Boezio M, Bogomolov EA, Bonechi L, Bongi M, Bonvicini V, Bottai S, Bruno A, Cafagna F, Campana D, Carlson P, Casolino M, Castellini G, De Pascale MP, De Rosa G, De Simone N, Di Felice V, Galper AM, Grishantseva L, Hofverberg P, Koldashov SV, Krutkov SY, Kvashnin AN, Leonov A, Malvezzi V, Marcelli L, Menn W, Mikhailov VV, Mocchiutti E, Orsi S, Osteria G, Papini P, Pearce M, Picozza P, Ricci M, Ricciarini SB, Simon M, Sparvoli R, Spillantini P, Stozhkov YI, Vacchi A, Vannuccini E, Vasilyev G, Voronov SA, Yurkin YT, Zampa G, Zampa N, Zverev VG. An anomalous positron abundance in cosmic rays with energies 1.5–100 GeV. Nature 2009; 458:607-9. [DOI: 10.1038/nature07942] [Citation(s) in RCA: 1589] [Impact Index Per Article: 105.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2008] [Accepted: 02/06/2009] [Indexed: 11/09/2022]
|
43
|
Jeha S, Pei D, Raimondi SC, Onciu M, Campana D, Cheng C, Sandlund JT, Ribeiro RC, Rubnitz JE, Howard SC, Downing JR, Evans WE, Relling MV, Pui CH. Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1. Leukemia 2009; 23:1406-9. [PMID: 19282835 DOI: 10.1038/leu.2009.42] [Citation(s) in RCA: 91] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
To evaluate the impact of contemporary therapy on the clinical outcome of children with pre-B acute lymphoblastic leukemia (ALL) and the t(1;19)/TCF3/PBX1, we analyzed 735 patients with B-cell precursor ALL treated in four successive protocols at St Jude Children's Research Hospital. The 41 patients with the t(1;19) had a comparable event-free survival to that of the 694 patients with other B-cell precursor ALL (P=0.63; 84.2+/-7.1% (s.e.) vs 84.0+/-1.8% at 5 years). However, patients with the t(1;19) had a lower cumulative incidence of any hematological relapse (P=0.06; 0 vs 8.3+/-1.2% at 5 years) but a significantly higher incidence of central nervous system (CNS) relapse (P<0.001; 9.0+/-5.1% vs 1.0+/-0.4% at 5 years). In a multivariate analysis, the t(1;19) was an independent risk factor for isolated CNS relapse. These data suggest that with contemporary treatment, patients with the t(1;19) and TCF3/PBX1 fusion have a favorable overall outcome but increased risk of CNS relapse.
Collapse
Affiliation(s)
- S Jeha
- Department of Oncology, St Jude Children's Research Hospital, Memphis, TN 38105, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Adriani O, Barbarino GC, Bazilevskaya GA, Bellotti R, Boezio M, Bogomolov EA, Bonechi L, Bongi M, Bonvicini V, Bottai S, Bruno A, Cafagna F, Campana D, Carlson P, Casolino M, Castellini G, De Pascale MP, De Rosa G, Fedele D, Galper AM, Grishantseva L, Hofverberg P, Leonov A, Koldashov SV, Krutkov SY, Kvashnin AN, Malvezzi V, Marcelli L, Menn W, Mikhailov VV, Minori M, Mocchiutti E, Nagni M, Orsi S, Osteria G, Papini P, Pearce M, Picozza P, Ricci M, Ricciarini SB, Simon M, Sparvoli R, Spillantini P, Stozhkov YI, Taddei E, Vacchi A, Vannuccini E, Vasilyev G, Voronov SA, Yurkin YT, Zampa G, Zampa N, Zverev VG. New measurement of the antiproton-to-proton flux ratio up to 100 GeV in the cosmic radiation. Phys Rev Lett 2009; 102:051101. [PMID: 19257498 DOI: 10.1103/physrevlett.102.051101] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/13/2008] [Revised: 11/21/2008] [Indexed: 05/27/2023]
Abstract
A new measurement of the cosmic-ray antiproton-to-proton flux ratio between 1 and 100 GeV is presented. The results were obtained with the PAMELA experiment, which was launched into low-Earth orbit on-board the Resurs-DK1 satellite on June 15th 2006. During 500 days of data collection a total of about 1000 antiprotons have been identified, including 100 above an energy of 20 GeV. The high-energy results are a tenfold improvement in statistics with respect to all previously published data. The data follow the trend expected from secondary production calculations and significantly constrain contributions from exotic sources, e.g., dark matter particle annihilations.
Collapse
Affiliation(s)
- O Adriani
- Physics Department of University of Florence, I-50019 Sesto Fiorentino, Florence, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Hochberg J, Mar B, Ayello J, Day N, van de Ven C, Ricci A, Gurnani L, Cairo E, Campana D, Cairo M. Significant Ex-Vivo Expansion of Cord Blood (CB) Natural Killer (NK) Cells and Concomitant Decrease in CB T-Cells by Genetically Reengineered K562 Cells (K562-mbIL15-41BBL). Biol Blood Marrow Transplant 2009. [DOI: 10.1016/j.bbmt.2008.12.135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
46
|
Lamba JK, Pounds S, Cao X, Downing JR, Campana D, Ribeiro RC, Pui CH, Rubnitz JE. Coding polymorphisms in CD33 and response to gemtuzumab ozogamicin in pediatric patients with AML: a pilot study. Leukemia 2008; 23:402-4. [PMID: 18615103 DOI: 10.1038/leu.2008.185] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
47
|
Campana D, Brocchi E, Tomassetti P. Multiple gastric endocrine tumours and gastrinomas of the duodenum in a patient with ZES MEN 1. Dig Liver Dis 2008; 40:476. [PMID: 18282753 DOI: 10.1016/j.dld.2007.11.030] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/27/2007] [Revised: 11/23/2007] [Accepted: 11/29/2007] [Indexed: 12/11/2022]
Affiliation(s)
- D Campana
- Department of Internal Medicine and Gastroenterology, University of Bologna, S.Orsola Malpighi Hospital, Via Massarenti 9, 40138 Bologna, Italy
| | | | | |
Collapse
|
48
|
Campana D, Nori F, Pezzilli R, Piscitelli L, Santini D, Brocchi E, Corinaldesi R, Tomassetti P. Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs. Endocr Relat Cancer 2008; 15:337-42. [PMID: 18310299 DOI: 10.1677/erc-07-0251] [Citation(s) in RCA: 58] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Gastric endocrine tumors associated with autoimmune chronic atrophic gastritis (gastric carcinoid type I) are almost exclusively benign lesions with little risk of deep invasion of the gastric parietal wall. For this reason, the role of octreotide in the treatment of these neoplastic lesions is controversial. Nine patients with more than five type I gastric endocrine tumors each <1 cm in size, without invasion of the muscularis propria and with Ki-67 index lower than 3%, were treated with long-acting somatostatin analogs for 12 months. After 6 months and again after 12 months, all the patients underwent upper gastrointestinal (GI) endoscopy with multiple biopsies. The plasma chromogranin A (CgA) levels and the gastrin levels in the serum were also determined. In all patients, the gastric neoplastic lesions disappeared after 12 months of somatostatin analog therapy. We also observed a significant reduction of CgA and gastrin levels at 6 and at 12 months of therapy as compared with the baseline values. We demonstrate that somatostatin analog treatment provokes the pathological regression of type I gastric carcinoids. This therapeutic approach should be considered as a valid option in selected patients with multiple type I gastric endocrine tumors.
Collapse
Affiliation(s)
- D Campana
- Dipartimento di Medicina Interna e Gastroenterologia and Dipartimento Clinico di Scienze Radiologiche ed Istopatologiche, Università di Bologna, Bologna, Italy
| | | | | | | | | | | | | | | |
Collapse
|
49
|
Brocchi E, Pezzilli R, Tomassetti P, Campana D, Corinaldesi R. Sedation during colonoscopy and the benefits of lubrication. Aliment Pharmacol Ther 2008; 27:207-8; author reply 208-9. [PMID: 17956595 DOI: 10.1111/j.1365-2036.2007.03559.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/08/2022]
|
50
|
Pezzilli R, Morselli-Labate AM, Fantini L, Campana D, Corinaldesi R. Assessment of the quality of life in chronic pancreatitis using Sf-12 and EORTC Qlq-C30 questionnaires. Dig Liver Dis 2007; 39:1077-86. [PMID: 17692582 DOI: 10.1016/j.dld.2007.06.014] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/02/2007] [Revised: 06/28/2007] [Accepted: 06/29/2007] [Indexed: 12/11/2022]
Abstract
BACKGROUND SF-12 Health Survey, and European Organisation for Research and Treatment of Cancer Quality of life Questionnaire-C30 are the two main questionnaires proposed and validated for assessing the quality of life in chronic pancreatitis. AIMS To evaluate the role of the information furnished by both the SF-12 Health Survey and European Organisation for Research and Treatment of Cancer Quality of life Questionnaire-C30 questionnaires, and to determine which of these two questionnaires may be considered more efficacious, in clinical practice, in describing the quality of life of patients with chronic pancreatitis. PATIENTS We studied 163 consecutive patients with proven chronic pancreatitis. METHODS The Italian version of the SF-12 Health Survey and the Italian neutral version of the European Organisation for Research and Treatment of Cancer Quality of life Questionnaire-C30 Version 3.0 questionnaires were administered. RESULTS Pancreatic pain was the only clinical variable able to significantly impair the SF-12 Health Survey component summaries as well as all domains of the European Organisation for Research and Treatment of Cancer Quality of life Questionnaire-C30, while body mass index was positively related to the physical component summary-12 and to the domains of the European Organisation for Research and Treatment of Cancer Quality of life Questionnaire-C30. A high level of reliability of the domains/scores of the two questionnaires in evaluating the quality of life in patients with chronic pancreatitis was found and two main factors were identified. These two factors were mainly related to the two SF-12 Health Survey summary components. CONCLUSIONS From a practical point of view, the SF-12 Health Survey is more reliable and easier to use in routine clinical practice than the European Organisation for Research and Treatment of Cancer Quality of life Questionnaire-C30.
Collapse
Affiliation(s)
- R Pezzilli
- Department of Internal Medicine and Gastroenterology, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
| | | | | | | | | |
Collapse
|